CN105232958B - Traditional Chinese medicine composition for preparing medicine for treating myasthenia gravis - Google Patents
Traditional Chinese medicine composition for preparing medicine for treating myasthenia gravis Download PDFInfo
- Publication number
- CN105232958B CN105232958B CN201510777945.9A CN201510777945A CN105232958B CN 105232958 B CN105232958 B CN 105232958B CN 201510777945 A CN201510777945 A CN 201510777945A CN 105232958 B CN105232958 B CN 105232958B
- Authority
- CN
- China
- Prior art keywords
- parts
- myrobalan
- chinese medicine
- myasthenia gravis
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 206010028417 myasthenia gravis Diseases 0.000 title claims abstract description 30
- 235000011517 Terminalia chebula Nutrition 0.000 claims description 48
- 235000015489 Emblica officinalis Nutrition 0.000 claims description 47
- 244000205574 Acorus calamus Species 0.000 claims description 34
- 235000011996 Calamus deerratus Nutrition 0.000 claims description 31
- 241000756042 Polygonatum Species 0.000 claims description 25
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 22
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 22
- 235000015655 Crocus sativus Nutrition 0.000 claims description 21
- 244000124209 Crocus sativus Species 0.000 claims description 21
- 235000013974 saffron Nutrition 0.000 claims description 20
- 239000004248 saffron Substances 0.000 claims description 20
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 15
- 241001170547 Sedum japonicum Species 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 244000235603 Acacia catechu Species 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 235000006226 Areca catechu Nutrition 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 244000119298 Emblica officinalis Species 0.000 claims 5
- 240000009088 Fragaria x ananassa Species 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 54
- 241000001522 Terminalia chebula Species 0.000 description 43
- 210000000952 spleen Anatomy 0.000 description 34
- 229940079593 drug Drugs 0.000 description 27
- 210000004072 lung Anatomy 0.000 description 25
- 210000003734 kidney Anatomy 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 241000220223 Fragaria Species 0.000 description 17
- 230000001737 promoting effect Effects 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 17
- 235000009508 confectionery Nutrition 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 240000005717 Dioscorea alata Species 0.000 description 13
- 235000002723 Dioscorea alata Nutrition 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 13
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 12
- 235000005487 catechin Nutrition 0.000 description 12
- 229950001002 cianidanol Drugs 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 235000019640 taste Nutrition 0.000 description 12
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 235000004879 dioscorea Nutrition 0.000 description 11
- 238000005728 strengthening Methods 0.000 description 11
- 244000270834 Myristica fragrans Species 0.000 description 10
- 235000009421 Myristica fragrans Nutrition 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 210000000936 intestine Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 240000006079 Schisandra chinensis Species 0.000 description 9
- 235000008422 Schisandra chinensis Nutrition 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000001702 nutmeg Substances 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- 241000220286 Sedum Species 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 235000005340 Asparagus officinalis Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241001522129 Pinellia Species 0.000 description 6
- 102000034337 acetylcholine receptors Human genes 0.000 description 6
- 235000006533 astragalus Nutrition 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 6
- 235000018553 tannin Nutrition 0.000 description 6
- 229920001864 tannin Polymers 0.000 description 6
- 239000001648 tannin Substances 0.000 description 6
- 241001273783 Carex scoparia Species 0.000 description 5
- 108010009685 Cholinergic Receptors Proteins 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 235000007056 Dioscorea composita Nutrition 0.000 description 5
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 5
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 5
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 5
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 5
- -1 For example Substances 0.000 description 5
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 5
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 241000208340 Araliaceae Species 0.000 description 4
- 241001061264 Astragalus Species 0.000 description 4
- 241001672694 Citrus reticulata Species 0.000 description 4
- 241000209020 Cornus Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000096284 Gynochthodes officinalis Species 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- UFCGDBKFOKKVAC-DSASHONVSA-N Schisantherin A Chemical compound O([C@H]1C=2C=C(C(=C(OC)C=2C2=C(OC)C=3OCOC=3C=C2C[C@H](C)[C@@]1(O)C)OC)OC)C(=O)C1=CC=CC=C1 UFCGDBKFOKKVAC-DSASHONVSA-N 0.000 description 4
- 244000193174 agave Species 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000006189 buccal tablet Substances 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000004575 stone Substances 0.000 description 4
- 210000004233 talus Anatomy 0.000 description 4
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 4
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 235000006480 Acorus calamus Nutrition 0.000 description 3
- 241000382455 Angelica sinensis Species 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 3
- 241000092665 Atractylodes macrocephala Species 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 241000190633 Cordyceps Species 0.000 description 3
- RTZKSTLPRTWFEV-OLZOCXBDSA-N Deoxygomisin A Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-OLZOCXBDSA-N 0.000 description 3
- 241001289529 Fallopia multiflora Species 0.000 description 3
- 244000307700 Fragaria vesca Species 0.000 description 3
- 240000004670 Glycyrrhiza echinata Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 3
- RTZKSTLPRTWFEV-UHFFFAOYSA-N Isokadsuranin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 RTZKSTLPRTWFEV-UHFFFAOYSA-N 0.000 description 3
- 241001522232 Pinellia ternata Species 0.000 description 3
- 240000008313 Pseudognaphalium affine Species 0.000 description 3
- 241001038562 Pseudostellaria heterophylla Species 0.000 description 3
- 241000405911 Rehmannia glutinosa Species 0.000 description 3
- 241000304406 Sedum bulbiferum Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001142 anti-diarrhea Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 229940076810 beta sitosterol Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 3
- JOZKFWLRHCDGJA-UHFFFAOYSA-N citronellol acetate Chemical compound CC(=O)OCCC(C)CCC=C(C)C JOZKFWLRHCDGJA-UHFFFAOYSA-N 0.000 description 3
- JEJFTTRHGBKKEI-OKILXGFUSA-N deoxyschizandrin Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-OKILXGFUSA-N 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930186755 gomisin Natural products 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 244000237330 gutta percha tree Species 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 230000037257 muscle growth Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- XZRVRYFILCSYSP-OAHLLOKOSA-N (-)-beta-bisabolene Chemical compound CC(C)=CCCC(=C)[C@H]1CCC(C)=CC1 XZRVRYFILCSYSP-OAHLLOKOSA-N 0.000 description 2
- WLNGPDPILFYWKF-OAHLLOKOSA-N (-)-beta-chamigrene Chemical compound C1CC(C)=CC[C@]21C(C)(C)CCCC2=C WLNGPDPILFYWKF-OAHLLOKOSA-N 0.000 description 2
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- YFESOSRPNPYODN-RSMWSHJLSA-N (2s,3s,4s,5r,6r)-6-[[(4s,6ar,6bs,8r,8ar,9r,10r,14br)-9-acetyloxy-8-hydroxy-4,8a-bis(hydroxymethyl)-4,6a,6b,11,11,14b-hexamethyl-10-[(z)-2-methylbut-2-enoyl]oxy-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-4-hydroxy-3,5-bis[[(2s,3r,4s, Chemical compound O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(\C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@H](O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)OC1CC[C@]2(C)C3CC=C4[C@@]([C@@]3(CCC2[C@]1(CO)C)C)(C)C[C@@H](O)[C@@]1(CO)[C@@H](OC(C)=O)[C@@H](C(CC14)(C)C)OC(=O)C(/C)=C/C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YFESOSRPNPYODN-RSMWSHJLSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 235000006020 Acacia catechu Nutrition 0.000 description 2
- 241001116477 Adenophora triphylla Species 0.000 description 2
- AXNVHPCVMSNXNP-GKTCLTPXSA-N Aescin Natural products O=C(O[C@H]1[C@@H](OC(=O)C)[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C AXNVHPCVMSNXNP-GKTCLTPXSA-N 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 244000003416 Asparagus officinalis Species 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 229920002361 Chebulic acid Polymers 0.000 description 2
- COZMWVAACFYLBI-UHFFFAOYSA-N Chebulic acid Natural products OC1=C(O)C(O)=C2C(C(CC(=O)O)C(O)=O)C(C(O)=O)OC(=O)C2=C1 COZMWVAACFYLBI-UHFFFAOYSA-N 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 240000007371 Cuscuta campestris Species 0.000 description 2
- XNEFHYFPRJBTJF-UHFFFAOYSA-N Dehydroshikimic acid Chemical compound OC1C=C(C(O)=O)CC(=O)C1O XNEFHYFPRJBTJF-UHFFFAOYSA-N 0.000 description 2
- 235000007877 Diospyros australis Nutrition 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 241000203475 Neopanax arboreus Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 241000037831 Polygonatum sibiricum Species 0.000 description 2
- 241000205407 Polygonum Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 235000010875 Prunus nigra Nutrition 0.000 description 2
- 235000004789 Rosa xanthina Nutrition 0.000 description 2
- 241000220222 Rosaceae Species 0.000 description 2
- 241000612118 Samolus valerandi Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000009330 Terminalia Nutrition 0.000 description 2
- 241001534869 Terminalia Species 0.000 description 2
- LSQXNMXDFRRDSJ-UHFFFAOYSA-N Thymol methyl ether Chemical compound COC1=CC(C)=CC=C1C(C)C LSQXNMXDFRRDSJ-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 235000018288 Vitex doniana Nutrition 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- AZQOQICAWOAGEN-ZOKDDAQRSA-N [(9S,10S)-10-hydroxy-4,5,14,15,16-pentamethoxy-9,10-dimethyl-3-tricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaenyl] benzoate Chemical compound C([C@H](C)[C@@](C)(O)CC=1C=C(C(=C(OC)C=1C1=2)OC)OC)C1=CC(OC)=C(OC)C=2OC(=O)C1=CC=CC=C1 AZQOQICAWOAGEN-ZOKDDAQRSA-N 0.000 description 2
- DKIOHPQGBJCENG-XOWTYJCDSA-N [(9S,10S,11R)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-11-yl] benzoate Chemical compound COc1cc2C[C@H](C)[C@H](C)[C@@H](OC(=O)c3ccccc3)c3cc4OCOc4c(OC)c3-c2c(OC)c1OC DKIOHPQGBJCENG-XOWTYJCDSA-N 0.000 description 2
- 239000001560 acacia catechu Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 description 2
- KDKJYYNXYAZPIK-UHFFFAOYSA-J aluminum potassium disulfate hydrate Chemical compound O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O KDKJYYNXYAZPIK-UHFFFAOYSA-J 0.000 description 2
- ZSAUXCVJDYCLRS-UHFFFAOYSA-N angeloylgomisin H Natural products C1C(C)(O)C(C)CC2=CC(OC)=C(OC)C(OC(=O)C(C)=CC)=C2C2=C1C=C(OC)C(OC)=C2OC ZSAUXCVJDYCLRS-UHFFFAOYSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000003056 antler Anatomy 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229930184515 benzoylisogomisin Natural products 0.000 description 2
- XZRVRYFILCSYSP-UHFFFAOYSA-N beta-Bisabolene Natural products CC(C)=CCCC(=C)C1CCC(C)=CC1 XZRVRYFILCSYSP-UHFFFAOYSA-N 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- COZMWVAACFYLBI-XJEVXTIOSA-N chebulic acid Chemical compound OC1=C(O)C(O)=C2[C@H]([C@H](CC(=O)O)C(O)=O)[C@@H](C(O)=O)OC(=O)C2=C1 COZMWVAACFYLBI-XJEVXTIOSA-N 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- JEJFTTRHGBKKEI-UHFFFAOYSA-N deoxyschizandrin Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC JEJFTTRHGBKKEI-UHFFFAOYSA-N 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- ZWRRJEICIPUPHZ-MYODQAERSA-N gomisin a Chemical group COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C[C@](C)(O)[C@@H](C)CC2=CC2=C1OCO2 ZWRRJEICIPUPHZ-MYODQAERSA-N 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 244000132619 red sage Species 0.000 description 2
- SGAWOGXMMPSZPB-UHFFFAOYSA-N safranal Chemical compound CC1=C(C=O)C(C)(C)CC=C1 SGAWOGXMMPSZPB-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- ZWRRJEICIPUPHZ-UHFFFAOYSA-N schisandrol B Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3CC(C)(O)C(C)CC2=CC2=C1OCO2 ZWRRJEICIPUPHZ-UHFFFAOYSA-N 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229930002600 steroidal saponin Natural products 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- ZSAUXCVJDYCLRS-QEEHVONISA-N tigloylgomisin h Chemical compound C1[C@](C)(O)[C@@H](C)CC2=CC(OC)=C(OC)C(OC(=O)C(\C)=C\C)=C2C2=C1C=C(OC)C(OC)=C2OC ZSAUXCVJDYCLRS-QEEHVONISA-N 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- NNWHUJCUHAELCL-SNAWJCMRSA-N trans-isomethyleugenol Chemical compound COC1=CC=C(\C=C\C)C=C1OC NNWHUJCUHAELCL-SNAWJCMRSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- FUCYIEXQVQJBKY-ZFWWWQNUSA-N (+)-δ-Cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(C)=C21 FUCYIEXQVQJBKY-ZFWWWQNUSA-N 0.000 description 1
- SIBCECUUMHIAAM-UHFFFAOYSA-N (+-)-alpha-Chamigren Natural products C1CC(C)=CCC21C(C)(C)CCC=C2C SIBCECUUMHIAAM-UHFFFAOYSA-N 0.000 description 1
- OGJPBGDUYKEQLA-NEPJUHHUSA-N (+/-)-gomisin m1 Chemical compound COC1=C2C=3C(O)=C(OC)C(OC)=CC=3C[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 OGJPBGDUYKEQLA-NEPJUHHUSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- YDZWHGJRWMQCDP-NKILCQAGSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3-hydroxy-4-[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-[(2s,3r,4 Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@]1(CCC(C[C@H]14)(C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YDZWHGJRWMQCDP-NKILCQAGSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- WRYLYDPHFGVWKC-JTQLQIEISA-N (R)-(-)-p-Menth-1-en-4-ol Natural products CC(C)[C@@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-JTQLQIEISA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- 229920000192 1,3,6-Trigalloyl glucose Polymers 0.000 description 1
- RNKMOGIPOMVCHO-SJMVAQJGSA-N 1,3,6-trigalloyl glucose Chemical compound C([C@@H]1[C@H]([C@@H]([C@@H](O)[C@H](OC(=O)C=2C=C(O)C(O)=C(O)C=2)O1)OC(=O)C=1C=C(O)C(O)=C(O)C=1)O)OC(=O)C1=CC(O)=C(O)C(O)=C1 RNKMOGIPOMVCHO-SJMVAQJGSA-N 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- CBQRQDRSNAPJKD-UHFFFAOYSA-N 2-ethyl-3,4,5-trihydroxybenzoic acid Chemical compound CCC1=C(O)C(O)=C(O)C=C1C(O)=O CBQRQDRSNAPJKD-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- ZPXHDWNADVHCRP-UHFFFAOYSA-N 6-Hydroxy-3alpha-(5-hydroxyangeloyloxy)-tremetone Natural products CC1=CCC(Br)C(C)(C)C11CC(Br)C(C)(Cl)CC1 ZPXHDWNADVHCRP-UHFFFAOYSA-N 0.000 description 1
- 241000722942 Acanthus montanus Species 0.000 description 1
- 241000544682 Acorus tatarinowii Species 0.000 description 1
- 241001633574 Adenophora stricta Species 0.000 description 1
- 235000007756 Akebia quinata Nutrition 0.000 description 1
- 240000008027 Akebia quinata Species 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- 241000226665 Anaphalis Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 1
- 235000002657 Artemisia tridentata Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 240000005343 Azadirachta indica Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 241000283007 Cervus nippon Species 0.000 description 1
- 229920002052 Chebulagic acid Polymers 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- JOZKFWLRHCDGJA-LLVKDONJSA-N Citronellyl acetate Natural products CC(=O)OCC[C@H](C)CCC=C(C)C JOZKFWLRHCDGJA-LLVKDONJSA-N 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 241000221751 Claviceps purpurea Species 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 241000207901 Cuscuta Species 0.000 description 1
- 244000013539 Cuscuta australis Species 0.000 description 1
- 241000110637 Cuscuta chinensis Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000732800 Cymbidium Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 235000002727 Dioscorea praehensilis Nutrition 0.000 description 1
- 235000002726 Dioscorea rotundata Nutrition 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 229930185889 Epigomisin Natural products 0.000 description 1
- GWDFJIBHVSYXQL-SYTFOFBDSA-N Epigomisin O Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3[C@H](O)[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 GWDFJIBHVSYXQL-SYTFOFBDSA-N 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 102100026535 Fibronectin type III domain-containing protein 5 Human genes 0.000 description 1
- 235000011591 Ficus hirta Nutrition 0.000 description 1
- 244000173782 Ficus hirta Species 0.000 description 1
- 241001092073 Filipendula Species 0.000 description 1
- 240000003362 Fragaria moschata Species 0.000 description 1
- 241001451126 Fragaria orientalis Species 0.000 description 1
- 235000012641 Fragaria vesca subsp vesca Nutrition 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- FYSHYFPJBONYCQ-OLZOCXBDSA-N Gomisin K3 Natural products O(C)c1c(OC)c2-c3c(O)c(OC)c(OC)cc3C[C@@H](C)[C@@H](C)Cc2cc1OC FYSHYFPJBONYCQ-OLZOCXBDSA-N 0.000 description 1
- OGJPBGDUYKEQLA-UHFFFAOYSA-N Gomisin M1 Natural products COC1=C2C=3C(O)=C(OC)C(OC)=CC=3CC(C)C(C)CC2=CC2=C1OCO2 OGJPBGDUYKEQLA-UHFFFAOYSA-N 0.000 description 1
- 244000299507 Gossypium hirsutum Species 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241001113425 Iridaceae Species 0.000 description 1
- 101800001026 Irisin Proteins 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001123258 Meretrix meretrix Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000498779 Myristica Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000700556 Polygonatum cathcartii Species 0.000 description 1
- 241001468611 Polygonatum cyrtonema Species 0.000 description 1
- RLRKIWSBYUZHIJ-UHFFFAOYSA-N Pregomisin Natural products OC1=C(OC)C(OC)=CC(CC(C)C(C)CC=2C=C(OC)C(OC)=C(O)C=2)=C1 RLRKIWSBYUZHIJ-UHFFFAOYSA-N 0.000 description 1
- IBXZKLJADNJZFN-UHFFFAOYSA-N Preschisanthrin Natural products COC1=C(O)C(OC)=CC(CC(C)C(C)CC=2C=C(OC)C(O)=C(OC)C=2)=C1 IBXZKLJADNJZFN-UHFFFAOYSA-N 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 235000011158 Prunus mume Nutrition 0.000 description 1
- 244000018795 Prunus mume Species 0.000 description 1
- 240000002577 Prunus nigra Species 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- VNYBTNPBYXSMOO-UHFFFAOYSA-M Pyridostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=C[N+](C)=C1 VNYBTNPBYXSMOO-UHFFFAOYSA-M 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 241001206332 Rhus potaninii Species 0.000 description 1
- 241001206339 Rhus punjabensis Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 241000736078 Schisandra sphenanthera Species 0.000 description 1
- UFCGDBKFOKKVAC-CEFZEKJPSA-N Schisantherin A Natural products O=C(O[C@@H]1[C@](O)(C)[C@H](C)Cc2c(c(OC)c3OCOc3c2)-c2c(OC)c(OC)c(OC)cc12)c1ccccc1 UFCGDBKFOKKVAC-CEFZEKJPSA-N 0.000 description 1
- 241001516602 Schlechtendalia chinensis Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- MZOWOHKNFKJFFD-RRFJBIMHSA-N Sesquicarene Chemical compound C1CC(C)=C[C@H]2[C@@](CCC=C(C)C)(C)[C@H]21 MZOWOHKNFKJFFD-RRFJBIMHSA-N 0.000 description 1
- OTWKACNCVAYEGM-UHFFFAOYSA-N Sibiricoside A Chemical compound O1C2CC3C4CC=C5CC(OC6C(C(O)C(OC7C(C(OC8C(C(O)C(O)CO8)O)C(O)C(CO)O7)OC7C(C(O)C(O)C(CO)O7)O)C(CO)O6)O)CCC5(C)C4CCC3(C)C2C(C)C1(OC)CCC(C)COC1OC(CO)C(O)C(O)C1O OTWKACNCVAYEGM-UHFFFAOYSA-N 0.000 description 1
- QURPLLAPNURGHG-UHFFFAOYSA-N Sibiricoside B Chemical compound O1C2(C(CC(C)CO2)O)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2(O)C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O QURPLLAPNURGHG-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 244000109420 Vitex doniana Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 108020000715 acetylcholine receptors Proteins 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- SIBCECUUMHIAAM-OAHLLOKOSA-N alpha-Chamigrene Chemical compound C1CC(C)=CC[C@]21C(C)(C)CCC=C2C SIBCECUUMHIAAM-OAHLLOKOSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- VLXDPFLIRFYIME-MWHZVNNOSA-N alpha-Ylangene Chemical compound C1C=C(C)C2[C@@]3(C)CCC(C(C)C)C2C31 VLXDPFLIRFYIME-MWHZVNNOSA-N 0.000 description 1
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 1
- 229930002992 alpha-chamigrene Natural products 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- VLXDPFLIRFYIME-QRTUWBSPSA-N alpha-ylangene Natural products C1C=C(C)[C@@H]2[C@@]3(C)CC[C@@H](C(C)C)[C@@H]2[C@H]31 VLXDPFLIRFYIME-QRTUWBSPSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- ZEMSHIOAFVYIFX-UHFFFAOYSA-N benzoylgomisin Q Natural products C12=CC(OC)=C(OC)C(OC)=C2C=2C(OC)=C(OC)C(OC)=CC=2CC(C)C(C)(O)C1OC(=O)C1=CC=CC=C1 ZEMSHIOAFVYIFX-UHFFFAOYSA-N 0.000 description 1
- RKFAZBXYICVSKP-UHFFFAOYSA-N beta- asarone Natural products COC1=CC(OC)=C(C=CC)C=C1OC RKFAZBXYICVSKP-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- RKFAZBXYICVSKP-WAYWQWQTSA-N beta-asarone Chemical compound COC1=CC(OC)=C(\C=C/C)C=C1OC RKFAZBXYICVSKP-WAYWQWQTSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- FYYCZOOGHMAZED-HNNXBMFYSA-N chamigrenol Natural products CC1(C)CCCC(=C)[C@]12CCC(=CC2)CO FYYCZOOGHMAZED-HNNXBMFYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000010227 chenpi Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- NNWHUJCUHAELCL-UHFFFAOYSA-N cis-Methyl isoeugenol Natural products COC1=CC=C(C=CC)C=C1OC NNWHUJCUHAELCL-UHFFFAOYSA-N 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000001209 crocus sativus l. Substances 0.000 description 1
- CQSSQGYZDLEMIF-UHFFFAOYSA-N cyclohexa-2,4-diene-1,1,4-triol Chemical compound OC1=CCC(O)(O)C=C1 CQSSQGYZDLEMIF-UHFFFAOYSA-N 0.000 description 1
- PUTCXBJUWNRWJH-UHFFFAOYSA-N cyclohexa-3,5-diene-1,1,2-triol Chemical compound OC1C=CC=CC1(O)O PUTCXBJUWNRWJH-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- YOCDGWMCBBMMGJ-UHFFFAOYSA-N delta-cadinene Natural products C1C=C(C)CC2C(C(C)C)CCC(=C)C21 YOCDGWMCBBMMGJ-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- DQHJNOHLEKVUHU-UHFFFAOYSA-N hexyl 3,4,5-trihydroxybenzoate Chemical compound CCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 DQHJNOHLEKVUHU-UHFFFAOYSA-N 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229930182790 isoschizandrin Natural products 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910001710 laterite Inorganic materials 0.000 description 1
- 239000011504 laterite Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 1
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940098295 nutmeg extract Drugs 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- RLRKIWSBYUZHIJ-OKILXGFUSA-N pregomisin Chemical compound OC1=C(OC)C(OC)=CC(C[C@H](C)[C@H](C)CC=2C=C(OC)C(OC)=C(O)C=2)=C1 RLRKIWSBYUZHIJ-OKILXGFUSA-N 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 229960002151 pyridostigmine bromide Drugs 0.000 description 1
- MZOWOHKNFKJFFD-UHFFFAOYSA-N rac-Sesquicaren Natural products C1CC(C)=CC2C(CCC=C(C)C)(C)C21 MZOWOHKNFKJFFD-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- GRHNKVUUWRVFMM-OYMPBJRDSA-N rubschisantherin Chemical compound COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3[C@H](OC(C)=O)[C@@H](C)[C@@H](C)CC2=CC2=C1OCO2 GRHNKVUUWRVFMM-OYMPBJRDSA-N 0.000 description 1
- GRHNKVUUWRVFMM-UHFFFAOYSA-N rubschizantherin Natural products COC1=C2C=3C(OC)=C(OC)C(OC)=CC=3C(OC(C)=O)C(C)C(C)CC2=CC2=C1OCO2 GRHNKVUUWRVFMM-UHFFFAOYSA-N 0.000 description 1
- 235000017509 safranal Nutrition 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229930192961 schisandrol Natural products 0.000 description 1
- FYSHYFPJBONYCQ-QWHCGFSZSA-N schisanhenol Chemical compound C1[C@H](C)[C@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-QWHCGFSZSA-N 0.000 description 1
- FYSHYFPJBONYCQ-UHFFFAOYSA-N schisanhenol Natural products C1C(C)C(C)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2O FYSHYFPJBONYCQ-UHFFFAOYSA-N 0.000 description 1
- 229930193195 schizandrin Natural products 0.000 description 1
- XDVOVYYAPHHHBE-YGIMCSHQSA-N schizantherin b Chemical compound C[C@@H]/1[C@](C)(O)[C@@H](OC(=O)C(\C)=C/C)C2=CC(OC)=C(OC)C(OC)=C2[C@H]2C(OC)=C(OCO3)C3=C\C2=C\1 XDVOVYYAPHHHBE-YGIMCSHQSA-N 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940124513 senna glycoside Drugs 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229930013921 sesquicarene Natural products 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- USDOQCCMRDNVAH-UHFFFAOYSA-N sigma-cadinene Natural products C1C=C(C)CC2C(C(C)C)CC=C(C)C21 USDOQCCMRDNVAH-UHFFFAOYSA-N 0.000 description 1
- 229910052604 silicate mineral Inorganic materials 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 108010038851 tannase Proteins 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域technical field
本发明涉及到中药组合物,是调节免疫系统功能的中药组合物,具体是用于制备治疗重症肌无力药物的中药组合物,涉及到中医药领域。The invention relates to a traditional Chinese medicine composition, which is a traditional Chinese medicine composition for regulating the function of the immune system, specifically a traditional Chinese medicine composition for preparing medicine for treating myasthenia gravis, and relates to the field of traditional Chinese medicine.
背景技术Background technique
免疫系统是机体保护自身的防御性结构,主要由淋巴器官(胸腺、淋巴结、脾、扁桃体)、其它器官内的淋巴组织和全身各处的淋巴细胞、抗原呈递细胞等组成。免疫系统具有高度的辨别力,能精确识别自己和非己物质,以维持机体的相对稳定性;同时还能接受、传递、扩大、储存和记忆有关免疫的信息,针对免疫信息发生正和负的应答并不断调整其应答性。免疫系统在人体内主要起着生理防御、自身稳定和免疫监视的作用,是人体抵御病原菌侵犯最重要的保卫系统。兔疫功能一旦失去平衡就容易产生疾病。免疫系统低下,易招致细菌、病毒、真菌的感染,免疫系统亢进则会诱发自身免疫疾病。The immune system is a defensive structure for the body to protect itself. It is mainly composed of lymphoid organs (thymus, lymph nodes, spleen, tonsils), lymphoid tissues in other organs, and lymphocytes and antigen-presenting cells throughout the body. The immune system has a high degree of discrimination and can accurately identify self and non-self substances to maintain the relative stability of the body; at the same time, it can also receive, transmit, expand, store and remember immune information, and respond positively and negatively to immune information And constantly adjust its responsiveness. The immune system mainly plays the role of physiological defense, self-stabilization and immune surveillance in the human body, and is the most important defense system for the human body to resist the invasion of pathogenic bacteria. Once the rabbit epidemic function is out of balance, it is easy to produce diseases. A low immune system can easily lead to bacterial, viral, and fungal infections, while an overactive immune system can induce autoimmune diseases.
快节奏、高效率的现代社会,常常使人们长期处于竞争激烈、心理压力大、超负荷运行的紧张状态中,这种状况如不能及时化解,则很容易产生生理和心理的疾病。当各种因素诱发免疫系统不能正常发挥保护作用时,就会造成免疫功能失衡。The fast-paced and high-efficiency modern society often keeps people in a tense state of fierce competition, high psychological pressure, and overloaded operation for a long time. If this situation cannot be resolved in time, it is easy to cause physical and psychological diseases. When various factors induce the immune system to fail to play a protective role normally, it will cause immune function imbalance.
重症肌无力是神经-肌肉处乙酰胆碱传导障碍引起的一种慢性、自身免疫性疾病,主要表现为某些横纹肌异常容易疲劳,通常在活动后加剧,休息后减轻。重症肌无力的病因目前尚有多种说法:其一,是神经突触后膜上乙酰胆碱受体(AchR)数目明显减少(约减少70-80%),并有抗受体蛋白存在,使受体发生退化,数目减少。其二,是受与AchR具有相同或相似表面抗原的病毒感染,引起了机体免疫系统过度应答,累及AchR,导致ArchR被破坏。其三,某些环境因素如环境污染造成免疫力紊乱;过渡劳累、情绪激动、长期营养不良等外在因素同样会导致重症肌无力的发生。Myasthenia gravis is a chronic, autoimmune disease caused by nerve-muscle acetylcholine conduction disorders. It is mainly manifested as abnormal fatigue in certain striated muscles, which is usually aggravated after activity and relieved after rest. There are still many theories about the cause of myasthenia gravis: one is that the number of acetylcholine receptors (AchR) on the post-synaptic membrane of nerves is significantly reduced (about 70-80%), and there are anti-receptor proteins, which make the affected The body degenerates and the number decreases. The second is infection by a virus with the same or similar surface antigen as AchR, which causes the body's immune system to overreact and involves AchR, leading to the destruction of ArchR. Third, certain environmental factors such as environmental pollution cause immune disorders; external factors such as excessive fatigue, emotional agitation, and long-term malnutrition can also lead to the occurrence of myasthenia gravis.
现代医学对于重症肌无力的治疗方法包括:Modern medical treatments for myasthenia gravis include:
1、胸腺切除术,重症肌无力患者90%以上有胸腺异常,胸腺切除是重症肌无力有效治疗手段之一,适用于在16~60岁之间发病的全身型、无手术禁忌证的重症肌无力患者,大多数患者在胸腺切除术后可获显著改善。1. Thymectomy, more than 90% of patients with myasthenia gravis have thymus abnormalities. Thymectomy is one of the effective treatment methods for myasthenia gravis. Weak patients, most patients improve significantly after thymectomy.
2、胆碱酯酶抑制剂,该类药物是对症治疗的药物,治标不治本,不能单药长期应用,用药方法应从小剂量渐增。常用的有甲基硫酸新斯的明、溴吡斯的明。2. Cholinesterase inhibitors. These drugs are used for symptomatic treatment. They treat the symptoms but not the root cause. They cannot be used as a single drug for a long time, and the dosage should be gradually increased from a small dose. Commonly used are neostigmine methyl sulfate, pyridostigmine bromide.
3、免疫抑制,常用的免疫抑制剂为:①肾上腺皮质类固醇激素:强的松、甲基强的松龙等;②硫唑嘌呤;③环抱素A;④环磷酸胺;⑤他克莫司。3. Immunosuppression, commonly used immunosuppressants are: ① adrenal corticosteroids: prednisone, methylprednisolone, etc.; ② azathioprine; ③ cyclosporine A; ④ cyclophosphamide; ⑤ tacrolimus .
4、血浆置换,通过将患者血液中乙酰胆碱受体抗体去除的方式,常用于暂时缓解重症肌无力患者出现的危重症状,如不辅助其他治疗方式,疗效不超过2个月。4. Plasma exchange, by removing the acetylcholine receptor antibody in the patient's blood, is often used to temporarily relieve the critical symptoms of patients with myasthenia gravis. If it is not assisted by other treatment methods, the curative effect will not exceed 2 months.
6、静脉注射免疫球蛋白,人类免疫球蛋白中含有多种抗体,可以中和自身抗体、调节免疫功能。其效果与血浆置换相当。6. Intravenous injection of immunoglobulin, human immunoglobulin contains a variety of antibodies, which can neutralize autoantibodies and regulate immune function. Its effect is comparable to that of plasma exchange.
当前,重症肌无力的中医治疗越来越受到重视。重症肌无力属“痿症”范畴。根据中医理论,在治疗上加用中医中药,可以减少免疫抑制剂带来的副作用,在重症肌无力的治疗上起着保驾护航的作用,而且能重建自身免疫功能之功效。At present, the traditional Chinese medicine treatment of myasthenia gravis is getting more and more attention. Myasthenia gravis belongs to the category of "atrophy". According to the theory of traditional Chinese medicine, adding traditional Chinese medicine to the treatment can reduce the side effects caused by immunosuppressants, play an escort role in the treatment of myasthenia gravis, and can rebuild the effect of autoimmune function.
中医认为疾病的发生、发展和转归取决于正邪的消长,与机体的免疫功能密切相关,从而提出了扶正祛邪的主要治病原则。早在两千年前的《内经》中指出“正气存内,邪不可干”的免疫学思想,《素问》评热病中指出“邪之所凑,其气必虚”。人体正气强盛,可以控制邪气,使其不能发病,即使发病也御邪气于体表,而病情较轻;相反,其正气虚弱,邪气则长驱直入,侵入脏腑,使病位深而病情重。正气强盛,抗病有力,则顶后良好;正气虚弱,无力抗邪,则预后不良。扶正是指扶助机体正气,增强体质,提高机体抗邪、抗病能力的一种治疗原则,通过增强正气的方法,驱邪外出,恢复健康状况。因此可见中医中的正气说和现代免疫学中的增强免疫力是一致的。Traditional Chinese medicine believes that the occurrence, development and outcome of diseases depend on the ups and downs of good and evil, and are closely related to the immune function of the body. As early as 2,000 years ago, the "Nei Jing" pointed out the immunological thought of "righteousness exists inside, and evil cannot be done". The human body’s righteousness is strong, which can control the evils, so that it can’t get sick, and even if it happens, it keeps the evils on the body surface, and the disease is mild. If the righteousness is strong and the disease resistance is strong, then the back will be good; if the righteousness is weak and unable to resist the evil, the prognosis will be poor. Fuzheng refers to a treatment principle that supports the body's righteousness, strengthens the physique, and improves the body's ability to resist evils and diseases. Therefore, it can be seen that the theory of righteousness in traditional Chinese medicine is consistent with the enhancement of immunity in modern immunology.
当前中医认为,重症肌无力的禀赋不足,后天失调,或情志刺激,或外邪所伤,或疾病失治误治,或病后失养,均可导致脾胃气虚,渐而积虚成损。因此,重症肌无力的病机主要为脾胃病损。脾胃为后天之本,气血化生之源,居于中焦,为气机升降出人之枢机。脾主升主运,脾虚气陷,则升举无力,上睑属脾,故提睑无力而下垂;脾主肌肉四肢,脾虚生化濡养不足,故四肢萎软不能随用;胃主降主纳,与脾相表里,脾虚胃亦弱,则升降之枢机不利,受纳无权,故纳呆溏泄,吞咽困难;脾气主升,上充于肺,积于胸中而为宗气(大气),司呼吸,贯百脉,中气下陷,胸中之大气难以接续,肺之包举无力,故气短不足以息,若胸中大气亦下陷,则气息将停,危在顷刻。The current TCM believes that myasthenia gravis lack of endowment, acquired disorders, or emotional stimulation, or injury by external pathogens, or untreated diseases, or lack of support after illness, can lead to deficiency of spleen and stomach qi, which gradually accumulates and becomes damaged. . Therefore, the pathogenesis of myasthenia gravis is mainly spleen and stomach damage. The spleen and stomach are the foundation of the acquired constitution, the source of qi and blood transformation, reside in the middle burner, and are the cardinal mechanism for the movement of qi up and down. The spleen governs ascending and transporting. If the spleen is deficient and qi sinks, the lifting and lifting will be weak. The upper eyelid belongs to the spleen, so the lifting of the eyelids will be weak and drooping. Satisfaction, which is related to the exterior and interior of the spleen, if the spleen is deficient and the stomach is also weak, the cardinal mechanism of ascending and descending will be unfavorable, and there will be no right to receive and receive, so the appetite will be loose and let out, and swallowing will be difficult; Qi) is responsible for respiration, runs through all the meridians, the Qi in the chest sinks, the Qi in the chest is difficult to continue, and the lungs are weak, so shortness of breath is not enough to breathe. If the Qi in the chest also sinks, the breath will stop, and the danger will be instant.
然而,现代医学的药物虽在一定程度上能够治疗或治愈部分免疫系统疾病,但对于顽固性疾病,效果较差,且长期服用此类免疫调节药,更容易使原本脆弱的平衡被彻底打破,以致终生服药。当前的中医药治疗重症肌无力,更多的是将中药作为辅助治疗手段,用以减少西医药治疗带来的副作用,减少患者痛苦,提高生活质量。目前,尚无单用中医药治疗重症肌无力的报道。However, although the drugs of modern medicine can treat or cure some immune system diseases to a certain extent, they are less effective for intractable diseases, and taking such immunomodulatory drugs for a long time is more likely to completely break the fragile balance. Take medicine for life. The current traditional Chinese medicine treatment of myasthenia gravis is more about using Chinese medicine as an adjuvant treatment to reduce the side effects caused by Western medicine treatment, reduce the pain of patients, and improve the quality of life. At present, there is no report on the treatment of myasthenia gravis with traditional Chinese medicine alone.
发明内容Contents of the invention
为克服现有技术中的不足,为治疗重症肌无力提供更好的药物,申请人现公开一种中药组合物。In order to overcome the deficiencies in the prior art and provide better drugs for the treatment of myasthenia gravis, the applicant now discloses a traditional Chinese medicine composition.
在经多年对重症肌无力的病机、病因和症状等的研究和治疗的过程中,申请人认为重症肌无力之病机在于:正气不足而又外邪入侵,而正气不足、脏气亏虚又是其根本之因。因此虚多贯穿于疾病的始末,但疾病起初多为实,在外邪伤脏之后,进而发展为虚。申请人经不断总结和反复摸索,提出了全新的重症肌无力中医治疗理论,即以固本扶正为先,提高机体自身对抗疾病的能力,再将邪气从各脏腑中引出,并引导下行,之后加快正气于体内的流动,补充因邪气的离去而使各脏的“气虚”。After many years of research and treatment on the pathogenesis, etiology, and symptoms of myasthenia gravis, the applicant believes that the pathogenesis of myasthenia gravis lies in: lack of righteousness and invasion of external evils, and lack of righteousness and deficiency of visceral qi It is also the root cause. Therefore deficiency and excess run through the beginning and end of the disease, but the disease is mostly excess at the beginning, and then develops into deficiency after external pathogens damage the viscera. After continuous summarization and repeated exploration, the applicant proposed a brand-new TCM treatment theory for myasthenia gravis, that is, to strengthen the foundation and strengthen the body first, improve the body's ability to fight the disease, and then draw out the evil energy from the viscera and guide it downward. Accelerate the flow of healthy energy in the body, replenish the "deficiency of energy" in various organs due to the departure of evil energy.
本发明所述的中药组合物如下所述:Chinese medicine composition of the present invention is as follows:
一种中药组合物,其特征在于,原料包括黄精1-45份、藏菖蒲1-25份、诃子1-37份、石菖蒲1-45份、毛诃子1-45份、东方草莓1-23份、藏红花1-10份,以及选自儿茶膏1-15份、珠芽景天1-29份、鼠曲草1-34份中的至少一种。A traditional Chinese medicine composition, characterized in that the raw materials include 1-45 parts of sealwort, 1-25 parts of Tibetan calamus, 1-37 parts of myrobalan, 1-45 parts of Shichangpu, 1-45 parts of myrobalan, 1 part of oriental strawberry - 23 parts, 1-10 parts of saffron, and at least one selected from 1-15 parts of catechin extract, 1-29 parts of Sedum japonicum, and 1-34 parts of Sagemus sageii.
进一步的,原料包括黄精1-45份、藏菖蒲1-25份、诃子1-37份、石菖蒲1-45份、毛诃子1-45份、东方草莓1-23份、藏红花1-10份,以及选自儿茶膏1-15份、珠芽景天1-29份、鼠曲草1-34份中的至少二种。Further, the raw materials include 1-45 parts of sealwort, 1-25 parts of Tibetan calamus, 1-37 parts of myrobalan, 1-45 parts of Shichangpu, 1-45 parts of myrobalan, 1-23 parts of oriental strawberry, 1-37 parts of saffron 10 parts, and at least two selected from 1-15 parts of catechin extract, 1-29 parts of Sedum japonicum, and 1-34 parts of Sagecrop.
进一步的,原料包括黄精1-45份、藏菖蒲1-25份、诃子1-37份、石菖蒲1-45份、毛诃子1-45份、东方草莓1-23份、藏红花1-10份、儿茶膏1-15份、珠芽景天1-29份、鼠曲草1-34份。Further, the raw materials include 1-45 parts of sealwort, 1-25 parts of Tibetan calamus, 1-37 parts of myrobalan, 1-45 parts of Shichangpu, 1-45 parts of myrobalan, 1-23 parts of oriental strawberry, 1-37 parts of saffron 10 parts, 1-15 parts of catechin paste, 1-29 parts of Sedum japonicum, and 1-34 parts of Sagemus.
更进一步的,各原料重量用量为黄精3-38份、藏菖蒲1-20份、诃子1-28份、石菖蒲1-37份、毛诃子1-40份、东方草莓1-18份、藏红花1-8份、儿茶膏1-10份、珠芽景天1-25份、鼠曲草1-30份。Further, the weight dosage of each raw material is 3-38 parts of Polygonatum, 1-20 parts of Tibetan Calamus, 1-28 parts of Myrobalan, 1-37 parts of Shichangpu, 1-40 parts of Myrobalan, 1-18 parts of Oriental Strawberry .
更进一步的,各原料重量用量为黄精8-30份、藏菖蒲5-17份、诃子5-20份、石菖蒲6-28份、毛诃子15-31份、东方草莓3-15份、藏红花2-6份、儿茶膏2-8份、珠芽景天1-10份、鼠曲草1-25份。Furthermore, the weight dosage of each raw material is 8-30 parts of Polygonatum, 5-17 parts of Tibetan Calamus, 5-20 parts of Myrobalan, 6-28 parts of Shichangpu, 15-31 parts of Myrobalan, 3-15 parts of Oriental Strawberry , 2-6 parts of saffron, 2-8 parts of catechin paste, 1-10 parts of Sedum japonicum, and 1-25 parts of sagera.
本中药组合物中,以黄精、藏菖蒲、诃子、石菖蒲、毛诃子、藏红花、鼠曲草为主,黄精具补气养阴、健脾润肺益肾之功,巩固机体基底,提高正气,提神;藏菖蒲温胃、消炎止痛,调节方中凉性的药物不至于矫枉过正而使胃受寒;诃子敛肺止咳、涩肠止泻、降火利咽,帮助黄精起补益固本之功;石菖蒲化湿开胃,开窍豁痰,助体内邪气排出;毛诃子清热解毒、收敛养血,调合诸药;藏红花活血化瘀、凉血解毒、解郁安神;东方草莓具止血、祛痰、燥脓的功效;这几味药协同作用,共同达到排毒扶正、滋养脏腑的功效、In this traditional Chinese medicine composition, Polygonatum, Tibetan Calamus, Myrobalan, Shichangpu, Myrobalan, Saffron, and Sage Herb are mainly used. Polygonatum has the functions of invigorating qi and nourishing yin, invigorating the spleen, moistening the lungs and kidneys, and consolidating the foundation of the body. Improve righteousness and refresh the mind; store calamus to warm the stomach, reduce inflammation and relieve pain, and adjust the cool medicine in the prescription so that the stomach will not catch cold; myrobalan restrains the lungs and relieves cough, astringent intestines and diarrhea, reduces fire and relieves throat, and helps Polygonatum to strengthen and solidify The merits of the root; Acorus calamus reduces dampness and appetizers, resuscitates and clears phlegm, and helps expel evil spirits in the body; Myrobalan root clears heat and detoxifies, astringes and nourishes blood, and blends various medicines; Saffron promotes blood circulation and removes blood stasis, cools blood and detoxifies, relieves depression and calms the nerves; Oriental strawberry has The effects of hemostasis, expectoration, and dry pus; these medicines work together to achieve the effects of detoxification, nourishing the viscera,
根据患者个体体质区别以及病证具体表现,可选择增加儿茶膏、鼠曲草以及珠芽景天等药材。儿茶膏具活血止血、止血生肌、收湿敛疮、清肺化痰的功效,与上述诸药协调,可增强药方对肺的功效,同时增加活血止血、生肌敛疮的功能,适用于患者伴发血肿、毒疮、溃烂等。鼠曲草镇咳祛痰,对肺部症状有缓解作用。珠芽景天具益气活血、通脉平喘的功效,与上述诸药协调,可增强药方的理气宣肺之功效,适用于胸闷气喘等症。此处的三味药均可根据情况独自添加或组合加入。According to the differences in the individual constitution of the patient and the specific symptoms of the disease, you can choose to add medicinal materials such as catechu paste, sage, and Sedum japonicum. Catechu ointment has the effects of promoting blood circulation and stopping bleeding, stopping bleeding and promoting muscle growth, dampness and sores, and clearing lung and reducing phlegm. Coordinating with the above-mentioned medicines, it can enhance the efficacy of the prescription on the lungs, and at the same time increase the functions of promoting blood circulation and stopping bleeding, promoting muscle growth and suppressing sores. It is suitable for In patients with hematoma, sores, ulcers and so on. Sagewort relieves cough and eliminates phlegm, and relieves lung symptoms. Sedum japonicum has the effects of nourishing qi and activating blood circulation, dredging the meridians and relieving asthma. Coordinating with the above-mentioned drugs, it can enhance the effect of regulating qi and promoting the lungs of the prescription, and is suitable for chest tightness and asthma. The three herbs here can be added alone or in combination according to the situation.
为强化本中药组合物其中一个方面的功效,本发明所提供的组合物还可以包含至少一种选自黄芪、五爪龙、太子参、白术、山药、绞股蓝。上述诸药均为具有补气、健脾、健胃等作用之一,将此类药物添入处方,能够特化处方对肺、脾的调养,适合气虚、脾胃受损的患者。In order to enhance the effect of one aspect of the traditional Chinese medicine composition, the composition provided by the present invention may also contain at least one selected from Astragalus, Pentazoa, Radix Pseudostellariae, Atractylodes Rhizome, Yam, and Gynostemma pentaphyllum. The above-mentioned medicines all have one of the effects of invigorating qi, strengthening the spleen, and strengthening the stomach. Adding these kinds of medicines into the prescription can specialize the care of the lung and spleen in the prescription, and is suitable for patients with qi deficiency and damaged spleen and stomach.
同样的,为强化本药方对脾、胃的滋养和调理,处方中还可增加包括法半夏、五味子、陈皮、乌梅、五倍子、赤石脂、肉豆蔻。上述药物均具健脾、开胃、理气或止泻作用之一。在临床实践中,有部分患者体虚气弱,致使脾胃受损,积食不化,食欲不振,影响了食物和营养的摄取,加剧了病情。加入这些药物能够增强本中药组合物对脾、胃的滋养和调理,治疗脾胃病变,能够调理消化道功能,增强食欲,提高营养摄取,增加机体自身抵抗疾病的能力。Similarly, in order to strengthen the nourishment and conditioning of the spleen and stomach in this prescription, the prescription can also include French pinellia, schisandra, tangerine peel, black plum, gallnut, red stone fat, and nutmeg. The above-mentioned medicines all have one of the effects of invigorating the spleen, appetizing, regulating qi or antidiarrheal. In clinical practice, some patients are physically weak and weak, resulting in damage to the spleen and stomach, inability to digest food and loss of appetite, which affects the intake of food and nutrition and aggravates the condition. The addition of these medicines can enhance the nourishment and regulation of the spleen and stomach by the traditional Chinese medicine composition, treat spleen and stomach lesions, regulate the function of the digestive tract, enhance appetite, improve nutrient intake, and increase the body's ability to resist diseases.
再有,为强化本药方的补益功效,处方中还可增加至少一种选自山萸肉、冬虫夏草、巴戟天、鹿茸、杜仲、菟丝子,熟地黄、当归、制何首乌、天冬、南沙参。上述药物具补阳、补阴和补血功效之一。临床实践中,因营养不良导致的重症肌无力,加入这些药物能够针对此类病证的治疗,但在实践中需分清患者的证型,辩证施治。Furthermore, in order to strengthen the tonic effect of this prescription, at least one selected from cornus, cordyceps sinensis, Morinda officinalis, antler, Eucommia, dodder, rehmannia glutinosa, angelica, Polygonum multiflorum, Asparagus, Nansha ginseng can be added to the prescription. . The above-mentioned medicine has one of effects of tonifying yang, tonifying yin and tonifying blood. In clinical practice, the addition of these drugs can treat myasthenia gravis caused by malnutrition, but in practice, it is necessary to distinguish the syndrome type of the patient and apply dialectical treatment.
另一方面,运用本发明提供的中药组合物,可选地添加合适的药学上可接受的辅料,可以制备能够治疗重症肌无力的中药制剂,其方法可以是任意常规的中药制剂生产方法,生产任何常规的剂型。考虑到患者的顺应性和药效,所述制剂优选为口服剂型,更优选为口含片、散剂、胶囊剂或口服液,更优选为口含片、散剂、口服液,最优选为散剂。On the other hand, using the traditional Chinese medicine composition provided by the present invention, optionally adding suitable pharmaceutically acceptable adjuvants, can prepare the traditional Chinese medicine preparation capable of treating myasthenia gravis, and its method can be any conventional Chinese medicine preparation production method, producing Any conventional dosage form. Considering the patient's compliance and efficacy, the preparation is preferably an oral dosage form, more preferably buccal tablet, powder, capsule or oral liquid, more preferably buccal tablet, powder, oral liquid, most preferably powder.
制剂的方法可以是:The method of preparation can be:
1)各原料经挑杂后,称取,分组放好备用;1) After the raw materials are selected, weigh them, group them and put them away for later use;
2)各组原料切段,分别研磨成粉,过2号标准筛;2) Cut each group of raw materials into sections, grind them into powder separately, and pass through a No. 2 standard sieve;
3)将粉末混合,即得所述药物活性成分组合物;3) mixing the powders to obtain the active pharmaceutical ingredient composition;
4)将3)得到的活性成分组合物,按标准制剂工序,依据所制剂型的不同添加药用辅料,进行加工制成制剂。4) The active ingredient composition obtained in 3) is processed into a preparation according to the standard preparation procedure, adding pharmaceutical excipients according to the different preparation types.
例如,将提供的中药组合物制备成散剂的方法为:使用提供的中药组合物,将各原料药切段、研磨成粉,混匀即得散剂。使用时,将所述散剂按用量标准取药,置于舌下含服,约5-10分钟后吞咽,在吞咽后30分钟方可饮水。For example, the method for preparing the provided traditional Chinese medicine composition into powder is as follows: use the provided traditional Chinese medicine composition, cut each raw material into sections, grind them into powder, and mix them to obtain the powder. When in use, the powder is taken according to the dosage standard, placed under the tongue for oral administration, swallowed after about 5-10 minutes, and can be drunk 30 minutes after swallowing.
再例如,将提供的中药组合物制备成口服液的方法:将提供的组合物经水煎煮,之后浓缩水煎液,再添加药学上可接受的矫味剂、掩味剂、稀释剂,如蔗糖、炼蜜等与之搭配,制成口服液,经灭菌后灌装成瓶。如何进行煎煮,遵循本领域的一般指导原则和惯用手段,例如处方中需添加肉豆蔻,则在煎煮时,肉豆蔻应后下。For another example, the method of preparing the provided traditional Chinese medicine composition into an oral liquid: decoct the provided composition with water, then concentrate the decoction, and then add pharmaceutically acceptable flavoring agents, taste-masking agents, and diluents, For example, sucrose, refined honey, etc. are matched with it to make oral liquid, which is sterilized and filled into bottles. How to decoct, follow the general guidelines and customary means in this field, for example, nutmeg needs to be added in the prescription, then when decocting, the nutmeg should be dropped.
再例如,将提供的中药组合物制备成口含片的方法:将提供的中药组合物粉末与适合的片剂辅料,如甘露醇、硬脂酸镁、糊精等,混合,湿法制粒,干燥、整粒,压片即得。For another example, the method of preparing the provided traditional Chinese medicine composition into buccal tablets: mix the provided traditional Chinese medicine composition powder with suitable tablet excipients, such as mannitol, magnesium stearate, dextrin, etc., and wet granulate, Drying, granulation, and tableting.
为了使组合物中各原料药更好的发挥药效,优选的对各原料药进行水提取或醇提取,如何选择提取的溶剂,遵循本领域的通常做法。如若选用了丹参,则对丹参进行水提取,取其水提液浓缩喷雾干燥得丹参水提物进行制剂;若选择肉豆蔻,则对肉豆蔻进行醇提取,取其醇提液经浓缩进行制剂。但这些不能用于限制本发明的保护范围。In order to make each raw drug in the composition better exert its medicinal effect, it is preferable to carry out water extraction or alcohol extraction for each raw drug, and how to choose the solvent for extraction follows the common practice in this field. If Danshen is selected, extract it with water, take its water extract, concentrate and spray-dry it to obtain the water extract of Salvia Miltiorrhiza for preparation; if you choose nutmeg, carry out alcohol extraction of nutmeg, take its alcohol extract and concentrate it for preparation . But these cannot be used to limit the protection scope of the present invention.
在没有中药提取条件的情况下,优选将提供的组合物制成口含片或散剂。In the absence of traditional Chinese medicine extraction conditions, the provided composition is preferably made into buccal tablets or powders.
本发明公开的中药制剂具有清热解毒、活血化瘀、润肺祛痰、健脾开胃、补益安神、止泻敛疮的功效,具有调节机体免疫力的能力,将失衡的免疫系统恢复正常,适用于因免疫失衡导致的疾病,尤其适合用于治疗重症肌无力。The traditional Chinese medicine preparation disclosed by the invention has the effects of clearing heat and detoxifying, promoting blood circulation and removing blood stasis, moisturizing the lungs and eliminating phlegm, invigorating the spleen and appetizing, nourishing the nerves, stopping diarrhea and suppressing sores, has the ability to regulate the immunity of the body, and restores the unbalanced immune system to normal. It is suitable for It is especially suitable for the treatment of myasthenia gravis in diseases caused by immune imbalance.
优选的,本发明所使用的组合物各组分用量为:黄精5-20份、藏菖蒲1-30份、诃子1-25份、石菖蒲1-25份、毛诃子1-25份、藏红花1-10份、鼠曲草1-35份,儿茶膏1-15份、东方草莓1-25份、珠芽景天1-12份。Preferably, the dosage of each component of the composition used in the present invention is: 5-20 parts of sealwort, 1-30 parts of Tibetan calamus, 1-25 parts of myrobalan, 1-25 parts of Shichangbu, 1-25 parts of myrobalan .
更优选的,本发明所使用的组合物各组分用量为:黄精8-18份、藏菖蒲3-27份、诃子3-22份、石菖蒲4-21份、毛诃子5-17份、藏红花1-7份、鼠曲草1-30份,儿茶膏2-12份、东方草莓1-22份、珠芽景天1-10份。More preferably, the dosage of each component of the composition used in the present invention is: Polygonatum 8-18 parts, Tibetan Calamus 3-27 parts, Myrobalan 3-22 parts, Shichangpu 4-21 parts, Maobula 5-17 parts 1-7 parts of saffron, 1-30 parts of sagera, 2-12 parts of catechin paste, 1-22 parts of oriental strawberry, 1-10 parts of Sedum japonicum.
本发明方案中涉及到的中药材说明如下:The Chinese medicinal material involved in the scheme of the present invention is described as follows:
黄精,为百合科黄精属植物黄精Polygonatum sibiricum、滇黄精Polygonatumkingianu Coll. Et Hemsl.或多花黄精Polygonatum cyrtonema Hua棒丝黄精Polygonatum cathcartii Baker.卷叶黄精P. cirrthifolium (Wall.)Royle和对叫黄精P.oppositifolium (Wall.) Royle的于燥根茎。按照形状不同,习称“大黄精”“鸡头黄精”“姜形黄精”。黄精具有补气养阴,健脾,润肺,益肾的功效。选用黄精时,能增加本方的补益功效,适用体虚、乏力、精神萎靡者。现代技术可从黄精根茎中分离出甾体皂甙,包括2个呋甾烯醇型皂甙和2个螺甾烯醇型皂甙。属于前者的是:26-O-β-D-吡喃葡萄糖基-22-O-甲基-(25)S-呋甾-5-烯-3β,26-二醇3-O-β-石蒜四糖甙(26-O-β-D-glucopyranosyl-22-O-methyl-25(S)-furost-5-ene-3β,26-diol3-O-β-lycotetraoside)即西伯利亚蓼甙A (sibiricoside-A)和26-O-β-D-吡喃葡萄糖基-22-O-甲基-25(S)-呋甾-5-烯-3β,14α,26-三醇 3-O-β-石蒜四糖甙(26-O-β-D-glucopyranosyl-22-O-methyl-25(S)-fruost-5-ene-3β,14α,26-triol 3-O-β-lycotetraoside)即14α-羟基西伯利亚蓼甙A(14α-hydroxysibiricoside A);属于后者的是:((23S,25R)螺甾-5-烯-3β,14α,23-三醇 3-O-β-lycotetraoside)即西伯利亚蓼甙 B(sibiricoside B)和新巴拉次薯蓣皂甙元-A3-O-β-石 蒜四糖甙(neoprazerigenin A 3-O-β-lycotetraoside)。另含黄精多糖A、B、C,三者的相对分子质量均大于20万,均由葡萄糖(glucose)、甘露糖(mannose)和半乳糖醛酸(galacturonicacid)按照摩尔比6:26:1缩合而成;又含黄精低聚糖A、B、C,相对分子质量分别为1630、862和472,系由果糖(fructose)与葡萄糖按摩尔比8:1.4:1和2:1缩合而成。黄精具有的功效与上述有效成分有关。Polygonatum, Polygonatum sibiricum, Polygonatum sibiricum, Polygonatum kingianu Coll. Et Hemsl. or Polygonatum cyrtonema Hua, Polygonatum cathcartii Baker. .oppositifolium (Wall.) The dry rhizome of Royle. According to different shapes, it is commonly called "Rhubarb Rhizome", "Chicken Head Polygonatum" and "Ginger-shaped Polygonatum". Polygonatum has the effects of invigorating qi and nourishing yin, invigorating the spleen, moistening the lungs and nourishing the kidney. When Huang Jing is selected, it can increase the tonic effect of this prescription, and is suitable for people with physical weakness, fatigue, and listlessness. Modern technology can isolate steroidal saponins from Rhizome of Polygonatum Rhizome, including 2 furostenol-type saponins and 2 spirosterenol-type saponins. Belonging to the former are: 26-O-β-D-glucopyranosyl-22-O-methyl-(25)S-furostan-5-ene-3β,26-diol 3-O-β-alpha Allicotetraoside (26-O-β-D-glucopyranosyl-22-O-methyl-25(S)-furost-5-ene-3β, 26-diol3-O-β-lycotetraoside) is Siberia Polygonum A ( sibiricoside-A) and 26-O-β-D-glucopyranosyl-22-O-methyl-25(S)-furostan-5-ene-3β,14α,26-triol 3-O-β -Lycotetraoside (26-O-β-D-glucopyranosyl-22-O-methyl-25(S)-fruost-5-ene-3β,14α,26-triol 3-O-β-lycotetraoside) ie 14α-Hydroxysiberian polyglycoside A (14α-hydroxysibiricoside A); belongs to the latter: ((23S,25R)spirosta-5-ene-3β,14α,23-triol 3-O-β-lycotetraoside) ie Siberian glycoside B (sibiricoside B) and neoprazerigenin - A3-O-β-lycotetraoside (neoprazerigenin A 3-O-β-lycotetraoside). It also contains polygonatum polysaccharides A, B, and C, all of which have a relative molecular mass greater than 200,000, and are all condensed by glucose, mannose, and galacturonic acid in a molar ratio of 6:26:1 It also contains polygonatum oligosaccharides A, B, and C, with relative molecular masses of 1630, 862, and 472, respectively, and is formed by condensation of fructose and glucose in molar ratios of 8:1.4:1 and 2:1. Polygonatum has effects related to the above active ingredients.
鼠曲草,为菊科鼠麴草属植物鼠曲草(Gnaphalium affine),又名鼠麴草。以干燥全草或花序入药,具镇咳祛痰的功效。在藏药经典《晶珠本草》中,鼠曲草其名被记载为“香青”,分为黄白二种。在《中国藏药》第三卷(青海省药品检验所、青海省藏医药研究所主编,上海科学技术出版社,1996年)记载,“甘达巴扎”白者为乳白香青(Anaphalis lactcaMaxim),黄者即为鼠曲草,二者均“治培根病,去痞瘤”。而香青为菊科香青属植物,香青属曾合并于鼠麴草属,二者主要以两性花不育为区别。由此可知,鼠曲草与香青在植物分类学上虽属于不同物种,但有极密切的亲缘关系,且具有相同的功效。因此,鼠曲草和香青可以互换使用。Gnaphalium affine is a plant of the genus Gnaphalium affine in the Asteraceae family, also known as Gnaphalium affine. The dried whole herb or inflorescence is used as medicine, which has the effect of antitussive and expectorant. In the Tibetan medicine classic "Jingzhu Materia Medica", the name of the sage grass is recorded as "Xiangqing", which is divided into two types: yellow and white. In the third volume of "Chinese Tibetan Medicine" (edited by Qinghai Provincial Institute of Drug Control and Qinghai Provincial Institute of Tibetan Medicine, Shanghai Science and Technology Press, 1996), it is recorded that the white of "Ganda Bazaar" is Milky White Fragrant Green (Anaphalis lactcaMaxim ), and the yellow one is sage grass, both of which "cure Bacon's disease and remove tumors". And Xiangqing is a plant of the genus Xiangqing in the family Asteraceae, and the genus Xiangqing was once merged with the genus Mirabilis, and the two are mainly distinguished by the sterility of hermaphrodite flowers. It can be seen from this that, although Shamrock and Cymbidium belong to different species in plant taxonomy, they have a very close relationship and have the same effect. Therefore, sagebrush and cypress are used interchangeably.
儿茶膏,为豆科金合欢属植物儿茶(Acacia catechu (L.f.)Willci.)的去皮枝、干的干燥煎膏,具有活血止痛,止血生肌,收湿敛疮,清肺化痰的功效。Catechu cream is the peeled branch and dried decoction of leguminous Acacia catechu ( Acacia catechu (Lf)Willci. ), which has the functions of promoting blood circulation and relieving pain, stopping bleeding and promoting granulation, reducing dampness and sores, clearing lungs and reducing phlegm effect.
珠芽景天,为景天科景天属植物珠芽景天(Sedum bulbiferum,别称马尿花),全草可入药,以其干燥根和根茎为优。具有益气活血、通脉平喘的功效。Sedum bulbiferum is Sedum bulbiferum (Sedum bulbiferum, also known as horse urine flower) of the genus Sedum in the Sedum family. The whole plant can be used as medicine, and its dry roots and rhizomes are the best. It has the effects of replenishing qi and activating blood circulation, dredging channels and relieving asthma.
诃子,为使君子科诃子属植物诃子(Terminalia chebula Retz.)的成熟果实,又称诃黎勒,微毛诃子。诃子具敛肺止咳、涩肠止泻、降火利咽的功效。在藏药系统中,诃子为最常用的藏药材,被奉为“藏药之王”。诃子的果实含鞣质23.60%-37.36%,内含:诃子酸,诃黎勒酸,鞣料云实精,诃子鞣质,2,3-O-连二没食子酰石榴皮鞣质,榄仁黄素,原诃子酸,葡萄糖没食子鞣甙,1,3,6-三没食子酰葡萄糖,没食子酸,并没食子酸等。又含三萜类成分:榄仁萜酸,诃王醇。还含莽草酸,去氢莽草酸,奎宁酸,三十碳酸,棕榈酸,没食子酸已酯,诃子次酸三已酯,胡萝卜甙,β-谷甾醇,阿拉伯糖,果糖,葡萄糖,蔗糖,鼠李糖和氨基酸等。另含番泻甙,诃子素以及鞣酸酶,多酚氧化酶,过氧化物酶,抗坏血酸氧化酶等。现代研究表明,诃子还具有一定的抗癌功效。Myrobalan, for the mature fruit of Terminalia chebula Retz., also known as Myrobalan, microhair Myrobalan. Myrobalan has the effects of astringing the lungs to relieve cough, astringent intestines to stop diarrhea, reducing fire and relieving sore throat. In the Tibetan medicine system, Myrobalan is the most commonly used Tibetan medicinal material, and is regarded as the "King of Tibetan Medicine". The fruit of myrobalan contains 23.60%-37.36% tannins, including: chebulic acid, chebulic acid, tanning material Yunshijing, chebulin, 2,3-O-digalloyl pomegranate tannin , Terminalia flavin, procheroic acid, glucose gallotannin, 1,3,6-trigalloyl glucose, gallic acid, and gallic acid, etc. It also contains triterpenes: terminalene acid, xayawangol. Also contains shikimic acid, dehydroshikimic acid, quinic acid, triacic acid, palmitic acid, hexyl gallate, trihexyl chebulinate, carotin, β-sitosterol, arabinose, fructose, glucose, sucrose , rhamnose and amino acids etc. It also contains sennoside, chebulin, tannase, polyphenol oxidase, peroxidase, ascorbic acid oxidase, etc. Modern research shows that Myrobalan also has certain anti-cancer effects.
石菖蒲,属天南星科菖蒲属禾草状多年生草本植物石菖蒲(Acorus tatarinowii)的干燥根,又名九节菖蒲、山菖蒲、药菖蒲、金钱蒲、菖蒲叶、水剑草、香菖蒲。石菖蒲根茎作药用。生长于海拔20米至2600米的地区,具有化湿开胃,开窍豁痰,醒神益智的功效。Acorus calamus belongs to the dry root of Acorus tatarinowii, a grass-like perennial herb of the genus Calamus in the family Araceae. The rhizome of Shichangpu is used for medicinal purposes. It grows at an altitude of 20 meters to 2600 meters. It has the effects of reducing dampness and appetizing, resuscitating phlegm, refreshing and improving intelligence.
藏红花,为鸢尾科番红花属植物藏红花(Crocus sativus L.)的干燥柱头,含有的藏红花酸(Crocitin)、藏红花醛(safranal)、藏红花素(Crocin)和藏红花苦素(Protocrocin),具有活血化瘀、凉血解毒、解郁安神。另外,现代技术研究表明,藏红花具有抑制癌症、调节免疫力、抗氧化的功能。Saffron, the dry stigma of Crocus sativus L. in the family Iridaceae, contains crocitin, safranal, crocin and protocrocin, which have the function of promoting blood circulation. Dispelling blood stasis, removing heat from blood and detoxifying, resolving stagnation and calming the nerves. In addition, modern technology research shows that saffron has the functions of inhibiting cancer, regulating immunity and anti-oxidation.
藏菖蒲,为天南星科植物藏菖蒲(Acorus calamus L.)的干燥根茎,具有温胃,消炎止痛的功效。藏菖蒲又称水菖蒲、白菖蒲、臭蒲、泥菖蒲、大菖蒲。藏菖蒲全株含多种有效成分,其根茎含挥发油,油中主要成分为α-细辛醚、β-细辛醚,全草其他部位也含有挥发油。另尚含维生素、棕榈酸、菖蒲苷混合脂肪酸及糖。现代药理试验结果表明,藏菖蒲具有安神镇静、抗惊厥和降温等作用。此外,尚有解平滑肌痉挛等药理作用。Tibetan calamus is the dried rhizome of Tibetan calamus (Acorus calamus L.), which has the effects of warming the stomach, reducing inflammation and relieving pain. Tibetan calamus is also known as water calamus, white calamus, stinky calamus, mud calamus, and large calamus. The whole plant of Tibetan calamus contains a variety of active ingredients, and its rhizomes contain volatile oil. The main components in the oil are α-asarone and β-asarone, and other parts of the whole plant also contain volatile oil. It also contains vitamins, palmitic acid, irisin mixed fatty acids and sugar. The results of modern pharmacological tests show that Tibetan calamus has the effects of calming the nerves, sedating, anticonvulsant and cooling. In addition, there are pharmacological effects such as relieving smooth muscle spasm.
毛诃子,为使君子科榄仁树属植物毗黎勒孔的干燥成熟果实,有清热解毒,收敛养血,调和诸药之功效。其乙醇提取物中,含有β-谷甾醇、没食子酸、鞣花酸、没食子酸乙酯、诃子酸(Chehulagic acid,C41H30O27)及糖类物质;另还从毛诃子中分离得到-强心的甾体皂甙成分。毛诃子的生理活性与上述有效成分有关。Fructus myrobalan, for the dry ripe fruit of Junziaceae Terminalia genus Pilelekon, has the effects of clearing heat and detoxifying, astringent and nourishing blood, and harmonizing various medicines. Its ethanol extract contains β-sitosterol, gallic acid, ellagic acid, ethyl gallic acid, Chehulagic acid (C41H30O27) and carbohydrates; it is also isolated from the fruit of myrobalan-cardiac steroidal saponins. The physiological activity of myrobalan is related to the above-mentioned active ingredients.
东方草莓,为蔷薇科草莓属植物东方草莓(Fragaria orientalis Losinsk)的干燥全草。具有止血、祛痰、燥脓的作用。东方草莓全草含有黄酮类化合物,并含大量的鞣质等。糖类5.0~7.0%,总酸量1.175~326%,果汁占果实的70~80%。在少数民族医药实践中,草莓(F.elatior Elark.),结根草莓(F. filipendula Hemsi.),欧洲草莓(F.vescaL.)可作为替代品使用。Oriental strawberry is the dried whole herb of the plant Fragaria orientalis Losinsk in the Rosaceae family. It has the functions of hemostasis, expectoration and dry pus. Oriental strawberry whole grass contains flavonoids, and contains a lot of tannin and so on. Sugars are 5.0-7.0%, total acid content is 1.175-326%, and fruit juice accounts for 70-80% of the fruit. In minority medicine practice, strawberry (F.elatior Elark.), rooted strawberry (F. filipendula Hemsi.), European strawberry (F.vescaL.) can be used as substitutes.
法半夏为天南星科半夏属植物半夏(Pinellia ternata (Thunb.) Breit.)的炮制品。炮制方法为:取净半夏,大小分开,浸泡10~12天,每日轻轻搅拌换水2次,至无干心,再用白矾水浸泡3天,去白矾水,用水再泡2天,加甘草、石灰液(取甘草20kg,加水煎煮2次,合并煎液,倒入用适量水制成的石灰液中)浸泡,每日搅拌1~2次,并保持pH 值为12.0以上,至口尝微有麻舌感,切面呈均匀黄色为度,取出,洗净,阴干或低温烘干。每100kg 净半夏,用甘草20kg、白矾2kg、生石灰30kg。该品呈类球形或破碎成不规则颗粒状。表面淡黄白色、黄色或棕黄色。质较松脆或硬脆,断面黄色或淡黄色,颗粒者质稍硬脆。气微,味淡略甘、微有麻舌感。Pinellia ternata (Pinellia ternata (Thunb.) Breit.) is a processed product of Pinellia ternata (Thunb.) Breit. The processing method is: take clean pinellia, separate the size, soak for 10-12 days, gently stir and change the water twice a day until there is no dryness, then soak in alum water for 3 days, remove the alum water, soak in water for another 2 days, Add licorice and lime solution (take 20kg of licorice, add water to decoct twice, combine the decoction, pour into the lime solution made with appropriate amount of water) to soak, stir 1-2 times a day, and keep the pH value above 12.0, There is a slight tongue numbness in the mouth, and the cut surface is evenly yellow. Take it out, wash it, and dry it in the shade or at low temperature. For every 100kg of net pinellia, 20kg of licorice, 2kg of alum, and 30kg of quicklime are used. The product is spherical or broken into irregular granules. The surface is light yellowish white, yellow or brownish yellow. The quality is relatively crisp or hard and brittle, the cross-section is yellow or light yellow, and the grains are slightly hard and brittle. Slight gas, light and slightly sweet taste, slightly numb tongue feeling.
半夏中分离可得到15个化合物,分别为大黄酚,丁二酸,正十六碳酸-1-甘油酯,3-O-(6'-O-棕榈酰基-β-D-吡喃葡萄糖基)豆甾-5-烯,对二羟基苯酚,羟甲基糠醛,邻二羟基苯酚及β-谷甾醇,胡萝卜苷。半夏所具备的药用作用与上述15个化合物有关。15 compounds can be obtained from the separation of pinellia, which are chrysophanol, succinic acid, n-hexadecanoic acid-1-glyceride, 3-O-(6'-O-palmitoyl-β-D-glucopyranosyl ) stigmaster-5-ene, p-dihydroxyphenol, hydroxymethylfurfural, o-dihydroxyphenol and β-sitosterol, carotene. The medicinal effects of pinellia are related to the above 15 compounds.
五味子为木兰科五味子属植物五味子(Schisandra chinensis (Turcz.)Baill)或华中五味子(Schisandra sphenanthera Rehd. et Wils.)的干燥成熟果实。前者称为北五味子,后者为南五味子,以北五味子为优。五味子具有敛肺滋肾,生津敛汗,涩精止泻,宁心安神的功效。现代技术对五味子成熟果实的分析,可以分离出多种有效成分。包括挥发性成分、木脂素类和有机酸类。亦含柠檬醛(Citrdal)、叶绿素、甾醇、维生素C、维生素E、糖类、树脂和鞣质。挥发性成分有:倍半蒈烯(Sesquicarene)、β-花柏烯(β-Chamigrene)、α-花柏烯(α-Cha migrene)、花柏醇(Chamigrenol)、β-甜没药烯(β-Bisabolene)、α-蒎烯(α-Pinene)、莰烯(Cam- phene)、β-蒎烯(β-Pinene)、月桂烯(Myrcene)、α-萜品烯(α-Terpinene)、柠檬烯(Limonene)、γ-萜品烯(γ-Terpinene)、对聚伞花烯(p-Cymene)、百里酚甲醚(Thymol methylether)、乙酸冰片酯(Bornyl acetate)、香茅醇乙酸酯(Citronellyl acetate)、芳樟醇(Linalool)、萜品烯-4-醇(Terpinene-4-ol)、α-萜品醇(α-Terpi- neol)、2-莰醇(Borneol)、香茅醇(Citronellol)、苯甲酸(Benzoic acid)、δ-荜澄茄烯(δ-Cadinene)、β-榄香烯(β- Elemene)、衣兰烯(α-Ylangene)等。木脂素类有:五味子素(Schizandrin)、去氧五味子素(Deoxyschizandrin)、γ-五味子素(γ-Schizandrin)、伪-γ-五味子素(Pseudo-γ-schizandrin)、五味子乙素(Wuweizisu B)、五味子丙素(Wuweizisu C)、异五味子素(Isoschizandrin)、前五味子素(Pregomisin)、新五味子素(Neoschizandrin)、五味子醇(Schizandrol)、五味子醇甲(Schizandrol A)、五味子醇乙(Schizandrol B 即Gomisin A)、五味子酯甲、乙、丙、丁、戊(Schisantherin A,B,C,D,E)、红花五味子酯(Rubschisantherin)、五味子酚酯(Schisanhenol acetdte)、五味子酚乙(Schisanhenol B)、五味子酚(Schisanhenol)。尚有戈米辛(Gomisin)A、B、C、D、E、F、G、H、J、N、O、R、S、T、U;表戈米辛(Epigomisin)O;当归酰戈米辛(Angeloylgomisin)H、O、Q;惕各酰戈米辛(Tigloylgomisin)H、P;当归酰异戈米辛(Angeloyisogomisin)O;苯甲酰戈米辛(Benzoyl- gomisin)H、O、P、Q;苯甲酰异戈米辛(Benzoyl- isogomisin)O等。Schisandra is the dry mature fruit of Schisandra chinensis (Turcz.) Baill or Schisandra sphenanthera Rehd. et Wils. The former is called northern schisandra, the latter is southern schisandra, and northern schisandra is the best. Fructus Schisandra has the effects of astringing the lungs and nourishing the kidneys, promoting body fluid and suppressing sweat, astringent essence and diarrhea, calming the mind and calming the nerves. The analysis of the mature fruit of Schisandra chinensis by modern technology can separate a variety of active ingredients. Including volatile components, lignans and organic acids. Also contains citral (Citrdal), chlorophyll, sterols, vitamin C, vitamin E, sugars, resins and tannins. The volatile components are: Sesquicarene, β-Chamigrene, α-Cha migrene, Chamigrenol, β-bisabolene ( β-Bisabolene), α-Pinene, Camphene, β-Pinene, Myrcene, α-Terpinene, Limonene, γ-Terpinene, p-Cymene, Thymol methylether, Bornyl acetate, Citronellol acetate Citronellyl acetate, Linalool, Terpinene-4-ol, α-Terpineol, 2-Borneol, Aroma Citronellol, Benzoic acid, δ-Cadinene, β-Elemene, α-Ylangene, etc. Lignans are: Schizandrin, Deoxyschizandrin, γ-Schizandrin, Pseudo-γ-schizandrin, Wuweizisu B ), Schisandrol C, Isoschizandrin, Pregomisin, Neoschizandrin, Schizandrol, Schizandrol A, Schizandrol B B is Gomisin A), Schisandrin A, B, C, D, E (Schisantherin A, B, C, D, E), Rubschisantherin, Schisandrin acetdte, Schisandrin B ( Schisanhenol B), Schisandrin (Schisanhenol). There are also Gomisin (Gomisin) A, B, C, D, E, F, G, H, J, N, O, R, S, T, U; Table Gomisin (Epigomisin) O; Angeloylgomisin H, O, Q; Tigloylgomisin H, P; Angeloyisogomisin O; Benzoylgomisin H, O, P, Q; Benzoyl-isogomisin (Benzoyl-isogomisin) O, etc.
陈皮为芸香科柑橘属植物橘(Citrus reticulata Blanco)及其栽培变种的干燥成熟果皮,本发明中选择加入陈皮,可使药方具有理气健脾,燥湿化痰的功能。在通常应用中,陈皮还可与苍术、厚朴同用,用于中焦寒湿脾胃气滞者,脘腹胀痛、恶心呕吐、泄泻;与山楂、神曲等同用,用于食积气滞,脘腹胀痛者;与枳实、生姜等同用,用于胸痹胸中气塞短气者。本领域技术人员可以依据实际的用药要求,根据此类配伍原则进行处方的加减、更改。Tangerine peel is the dry and mature peel of Citrus reticulata Blanco and its cultivars of Rutaceae. The addition of dried orange peel in the present invention can make the prescription have the functions of regulating qi, invigorating spleen, drying dampness and resolving phlegm. In general application, dried tangerine peel can also be used together with Atractylodes atractylodes and Magnolia officinalis for stagnation of spleen and stomach Qi due to cold and dampness in the middle Jiao, abdominal distension and pain, nausea and vomiting, and diarrhea; Patients with abdominal distension and pain; it is used with Citrus aurantium and ginger, and it is used for chest obstruction and shortness of breath. Those skilled in the art can add, subtract, and modify prescriptions according to such compatibility principles according to actual medication requirements.
乌梅为蔷薇科杏属植物梅(Prunus mume(Sieb.)Sieb.etZuce)的干燥近成熟果实。具有敛肺,涩肠,生津,安蛔的功效。Black plum is the dry near-ripe fruit of Prunus mume (Sieb.) Sieb. et Zuce, a plant of the genus Prunus in the Rosaceae family. It has the effects of astringing the lungs, astringing the intestines, promoting body fluid, and soothing roundworms.
五倍子为漆树科盐肤木属植物盐肤木(Rhus chinensis Mill.)、青麸杨(Rhuspotaninii Maxim.)或红麸杨(Rhus punjabensis Stew.var.sinica(Diels) Rehd.etWils.)叶上的虫瘿,主要由五倍子蚜(Melaphis chinensis(Bell)Baker)寄生而形成。又称文蛤、百虫仓、木附子、盐麸叶、上毬子。具有敛肺降火,涩肠止泻,敛汗,止血,收湿敛疮的功效。现代技术从五倍子中分理出多种物质,被证明的主要活性物质包括:五倍子单宁、没食子酸等。其中五倍子单宁被证明具有抑菌、抗龋齿、抑制突变、清除自由基和抗氧化的作用。Gallnut is the plant on the leaves of Rhus chinensis Mill., Rhuspotaninii Maxim. or Rhus punjabensis Stew.var.sinica (Diels) Rehd.etWils. Galls are mainly formed by gall aphid (Melaphis chinensis (Bell) Baker) parasitism. Also known as Meretrix Meretrix, Baichongcang, Mufuzi, Salt Bran Leaf, and Shangzhuzi. It has the effects of astringing the lungs and reducing fire, astringent intestines and diarrhea, sweating, hemostasis, dampness and sores. Modern technology separates a variety of substances from Gallnut, and the main proven active substances include: Gallnut tannin, gallic acid, etc. Among them, Gallic tannin has been proved to have the functions of antibacterial, anti-caries, inhibition of mutation, scavenging free radicals and anti-oxidation.
赤石脂为硅酸盐类矿物多水高岭石族多水高岭石,别名赤符、红高岭、赤石土、红土。主含四水硅酸铝,具有涩肠,止血,生肌敛疮之功效。实际应用中,赤石脂还可经锻制,增强止血、止泻、收敛作用。煅赤石脂的通常制备方法为:取赤石脂细粉,用醋调匀,搓条,切段,干燥,照明煅法(药物煅制时,不隔绝空气的方法称为明缎法。)煅至红透即成。用时捣碎。Chishizhi is a silicate mineral kaolinite group kaolinite, also known as Chifu, Hongkaolin, Chishi soil, and laterite. It mainly contains aluminum silicate tetrahydrate, which has the effects of astringent intestines, hemostasis, promoting granulation and astringing sores. In practical application, red stone fat can also be forged to enhance hemostatic, antidiarrheal and astringent effects. The usual preparation method of calcined red stone resin is: take fine red stone resin powder, mix thoroughly with vinegar, rub strips, cut into sections, dry, illuminated calcined method (when the medicine is calcined, the method of not isolating the air is called the bright satin method.) calcined to Completely red. Mash when used.
肉豆蔻为肉豆蔻科肉豆蔻属植物肉豆蔻(Myristica fragrans Houtt.)的干燥种仁,有温中行气,涩肠止泻的功效。生肉豆蔻油脂较多,有部分滑肠作用,经面裹、麦麸裹或滑石粉裹后煨制,可除去大部分油脂,消除滑肠作用,更加强了涩肠止泻的功效。现代技术可从肉豆蔻提取物中分离出甲基丁香酚和甲基异丁香酚,是肉豆蔻止泻的有效成分。Nutmeg is the dry seed kernel of Myristica fragrans Houtt., a plant of the Myristica family Myristica fragrans Houtt. Raw nutmeg has a lot of oil, which can partially smooth the intestines. After being wrapped in flour, wheat bran or talc powder, it can be simmered to remove most of the fat, eliminate the intestines smoothing effect, and further strengthen the effect of astringent intestines and diarrhea. Modern technology can separate methyl eugenol and methyl isoeugenol from nutmeg extract, which are the effective ingredients of nutmeg for antidiarrheal.
黄芪,为豆科黄芪属黄耆亚属黄耆(Astragalus membranaceus (Fisch.)Bunge.)的主根,别称棉芪,黄耆,独椹,蜀脂,百本,百药棉,黄参,血参,人衔等,黄芪味甘,性微温,归肺、脾、肝、肾经。具有补气升阳,益卫固表,利水消肿,托疮生肌的功效Astragalus, the main root of Astragalus membranaceus (Fisch.) Bunge., is the main root of Astragalus membranaceus (Fisch.) Bunge. , people's title, etc., Astragalus is sweet in taste, slightly warm in nature, and returns to the lung, spleen, liver, and kidney channels. It has the effects of invigorating qi and raising yang, benefiting health and solidifying the surface, diuresis and detumescence, healing sores and promoting muscle growth
五爪龙,为桑科榕属植物粗叶榕(Ficus hirta Vahl)的根,别名三龙爪、亚桠、五指毛桃、五指牛奶。味辛甘、性平、微温,具健脾补肺、行气利湿、舒筋活络的功效。岭南地区的中医或少数民族民间医生常用于治疗脾虚浮肿、食少无力、肺痨咳嗽、盗汗、带下、产后无乳、月经不调、风湿痹痛、水肿等症。Five-clawed Dragon is the root of Ficus hirta Vahl, a plant belonging to the genus Moraceae. It is also known as Sanlongclaw, Subcomb, Five-finger Maotao, and Five-finger Milk. Spicy and sweet in taste, flat in nature and slightly warm, it has the effects of invigorating the spleen and nourishing the lungs, promoting qi and dampness, relaxing tendons and activating collaterals. Traditional Chinese medicine or minority folk doctors in the Lingnan area are often used to treat spleen deficiency and edema, lack of food and weakness, tuberculosis cough, night sweats, vaginal discharge, postpartum angalactia, irregular menstruation, rheumatic arthralgia, edema and other diseases.
太子参,为石竹科孩儿参属植物孩儿参(Pseudostellaria heterophylla (Miq.)Pax ex Pax et Hoffm.)的干燥块根,别名孩儿参、童参、双批七、四叶参、米参。太子参味甘、微苦,性平,归脾肺经,具补气生津的功效。Pseudostellaria heterophylla (Pseudostellaria heterophylla (Miq.) Pax ex Pax et Hoffm.) is the dry tuberous root of Pseudostellaria heterophylla (Miq.) Pax ex Pax et Hoffm. Pseudostellariae Radix Pseudostellariae is sweet, slightly bitter, mild in nature, belongs to the spleen and lung meridian, and has the effect of invigorating qi and promoting body fluid.
白术,为菊科苍术属植物白术(Atractylodes macrocephala Koidz.),别称桴蓟,于术,冬白术,淅术,杨桴,吴术,山蓟、杨枹蓟、山芥。味苦、甘,性温,归脾胃经,具补气健脾,燥湿利水,固表止汗,安胎的功效。Atractylodes macrocephala is a plant of the genus Atractylodes macrocephala (Atractylodes macrocephala Koidz.) in the family Asteraceae, also known as Jiji, Yushu, Dongbaizhu, Xizhu, Yangzhu, Wushu, mountain thistle, Yangjiaoji, and mountain mustard. Bitter, sweet, warm in nature, it belongs to the Spleen and Stomach Meridian, and has the effects of invigorating qi and invigorating the spleen, drying dampness and diuresis, solidifying the surface, antiperspirant, and preventing miscarriage.
山药,为薯蓣科植物山药(Common Yam Rhizome)的根,别名薯蓣、土薯、山薯蓣、怀山药、淮山、白山药、水山药、毛山药、光山药。味甘,性平,归脾肺肾经,具有益气养阴,补脾肺肾,固精止遗的功效。Yam is the root of the yam (Common Yam Rhizome) of the yam family. It is also known as yam, yam, yam, Huai yam, Huai yam, white yam, water yam, hairy yam, and light yam. Sweet in taste, flat in nature, belongs to the spleen, lung and kidney meridians, has the effects of nourishing qi and nourishing yin, nourishing the spleen, lung and kidney, strengthening essence and arresting nocturnal emission.
绞股蓝,葫芦科绞股蓝属草质攀援植物绞股蓝(Gynostemma pentaphyllum(Thunb.) Makino)全草,又称:天堂草、福音草、超人参、公罗锅底、遍地生根、七叶胆、五叶参和七叶参等。味苦、微甘,性凉,归肺、脾、肾经。具有健脾益气,化痰止咳,清热解毒的功效。Gynostemma, Gynostemma pentaphyllum (Thunb.) Makino, a herbaceous climbing plant of the family Cucurbitaceae, is also known as: paradise grass, gospel grass, super ginseng, compass bottom, rooting everywhere, aescin, five-leaf ginseng and Aescin etc. Bitter in the mouth, slightly sweet, cool in nature, it returns to the lung, spleen, and kidney meridians. It has the effects of invigorating the spleen and replenishing qi, resolving phlegm and relieving cough, clearing heat and detoxifying.
山萸肉,为山茱萸科山茱萸属植物山茱萸(Cornus officinalis Sieb. etZucc.)的干燥成熟果肉,别称山萸肉、肉枣、鸡足、萸肉、药枣、天木籽、实枣儿、蜀枣、鬾实、鼠矢、枣皮、萸肉。味酸,(涩),性微温,归肝肾经。具有补益肝肾,收敛固涩的功效。Cornus is the dried and mature pulp of Cornus officinalis Sieb. et Zucc., a plant of the genus Cornus in the family Cornaceae. Jujube, scorpion, rat arrow, jujube skin, cornus. Sour in taste, (astringent), slightly warm in nature, returns to Liver and Kidney meridians. It has the effects of nourishing the liver and kidney, astringent and astringent.
冬虫夏草,为麦角菌科真菌冬虫夏草菌(Cordyceps sinensis(Berk.)Sacc)寄生在蝠蛾幼虫,幼虫僵死后,虫体与菌座相连而成。又称虫草,冬虫草,中华虫草,是我国民间惯用的一种名贵滋补药材。冬虫夏草味甘,性平,归肺肾经,具有益肾壮阳,补肺平喘,止血化痰的功效。Cordyceps sinensis is the ergot fungus Cordyceps sinensis (Berk.) Sacc that parasitizes the larvae of the bat moth. Also known as Cordyceps, Cordyceps, and Chinese Cordyceps, it is a rare and precious nourishing medicinal material commonly used by Chinese folks. Cordyceps sinensis is sweet in taste and flat in nature, and belongs to the lung and kidney channels.
巴戟天,为茜草科巴戟天属植物巴戟天(Morinda officinalis How)的干燥根,别称鸡肠风、鸡眼藤、黑藤钻、兔仔肠、三角藤、糠藤。巴戟天味辛,甘;性微温。归肾,肝经,具有补肾助阳,祛风除湿,强筋健骨的功效。Morinda officinalis How is the dry root of Morinda officinalis How in Rubiaceae, also known as Jichangfeng, corn vine, black vine drill, rabbit intestine, triangular vine, and bran vine. Morinda officinalis is pungent in taste, sweet; slightly warm in nature. Return kidney, liver meridian, have the effect of tonifying kidney and supporting yang, expelling wind and removing dampness, strengthening muscles and strengthening bones.
鹿茸,是指梅花鹿或马鹿的雄鹿未骨化而带茸毛的幼角。味甘、咸,性温,归肾肝经,具有壮肾阳,益精血,强筋骨,调冲任,固带脉,托疮毒的功效Antler refers to the unossified and hairy young horns of the sika deer or red deer stag. Sweet, salty, warm in nature, it belongs to the kidney and liver meridians, and has the effects of strengthening kidney yang, benefiting essence and blood, strengthening muscles and bones, regulating Chong and Ren, strengthening the veins, and treating sores
杜仲,为杜仲科杜仲属植物杜仲(Eucommia ulmoides Oliver)的干燥树皮,别称丝楝树皮、丝棉皮、棉树皮、胶树。味甘,性温,归肝、肾经,具补肝肾,强筋骨,安胎的功效。Eucommia ulmoides is the dry bark of Eucommia ulmoides Oliver (Eucommia ulmoides Oliver), also known as silk neem bark, silk cotton bark, cotton bark, and gum tree. Sweet in taste, warm in nature, it belongs to the liver and kidney meridians, and has the effects of nourishing the liver and kidney, strengthening bones and muscles, and preventing miscarriage.
菟丝子,为旋花科植物南方菟丝子(Cuscuta australis R.Br).或菟丝子(Cuscuta chinensis Lam.)的干燥成熟种子,别称菟丝实、吐丝子、无娘藤米米、黄藤子。味甘,性温,归肝肾脾经,具有补肾固精,养肝明目,止泻,安胎的功效。Cuscuta is the dried and mature seed of Cuscuta australis R.Br. or Cuscuta chinensis Lam. of Convolvulaceae. Sweet in taste and warm in nature, it belongs to the spleen meridian of liver, kidney, and has the effects of nourishing the kidney and strengthening essence, nourishing the liver and improving eyesight, stopping diarrhea and preventing miscarriage.
熟地黄,为玄参科地黄属植物地黄(Rehmannia glutinosa (Gaetn.) Libosch.ex Fisch. et Mey.)根部经熏蒸至黑润而得,味甘;性温。归肝;肾经。具有补血滋润、益精填髓的功效。Rehmannia glutinosa, obtained from the root of Rehmannia glutinosa (Gaetn.) Libosch.ex Fisch. et Mey., which is a plant of the family Scrophulariaceae, is sweet and warm in nature. Return liver; Kidney channel. It has the effects of nourishing blood, nourishing essence and filling marrow.
当归,为伞形科当归属植物当归(Angelica sinensis (Oliv.) Diels)的干燥根,别名干归、秦哪、西当归、岷当归、金当归、当归身、涵归尾、当归曲、土当归,味甘、辛,性温,归肝心脾经,具有补血活血、调经止痛、润燥滑肠的功效。Angelica sinensis is the dry root of Angelica sinensis (Oliv.) Diels, a plant of the genus Angelica sinensis (Oliv.) Diels. Angelica, sweet in taste, pungent, warm in nature, belongs to the liver, heart and spleen meridian, has the effects of nourishing blood and promoting blood circulation, regulating menstruation and relieving pain, moistening dryness and smoothing intestines.
制何首乌,为蓼科何首乌属植物何首乌(Fallopia multiflora (Thunb.)Harald)块根的炮制品,味苦、甘、涩,性温。归肝、心、肾经。具有补肝肾,益精血,乌须发,强筋骨的功效。Radix Polygoni Multiflori is the processed product of Polygonum multiflora (Fallopia multiflora (Thunb.) Harald) tuber root. It tastes bitter, sweet, astringent and warm in nature. Return liver, heart, kidney channel. It has the effects of invigorating liver and kidney, benefiting essence and blood, black beard and hair, and strengthening muscles and bones.
天冬,为百合科天门冬属植物天门冬(Asparaguscochinchinensis(Lour.)Merr.)的块根。别名天门冬,天冬性寒,味甘,微苦。具有养阴清热,润肺滋肾的功效。Asparagus is the root tuber of Asparagus chinchinensis (Lour.) Merr. in the family Asparagus. Also known as asparagus winter, asparagus is cold in nature, sweet in taste, slightly bitter. It has the effects of nourishing yin and clearing away heat, nourishing the lungs and nourishing the kidneys.
南沙参,为桔梗科沙参属植物轮叶沙参(Adenophora tetraphylla(Thunb.)Fisch.)或沙参(Adenophora stricta Miq.)的干燥根,轮叶沙参产于东北、内蒙古、河北、山西、山东、华东、广东、广西、云南、四川、贵州;沙参产于江苏、安徽、浙江、江西、湖南。味甘,性微寒,归肺胃经,具有养阴清肺,益胃生津,化痰,益气之功效。Adenophora tetraphylla (Thunb.) Fisch. or Adenophora stricta Miq. is the dried root of Adenophora tetraphylla (Thunb.) Fisch., which is produced in Northeast China, Inner Mongolia, Hebei, and Shanxi. , Shandong, East China, Guangdong, Guangxi, Yunnan, Sichuan, and Guizhou; sand ginseng is produced in Jiangsu, Anhui, Zhejiang, Jiangxi, and Hunan. Sweet in taste, slightly cold in nature, it belongs to the lung and stomach meridian, has the effects of nourishing yin and clearing lung, benefiting stomach and promoting body fluid, reducing phlegm and replenishing qi.
具体实施例specific embodiment
以下通过数个实施例进一步说明本发明。应当理解,所列举的所有实施例均为帮助本领域技术人员理解和实施本发明,并非任何形式的对本发明的任何限制。一切在本发明基础上进行的简单改进和调整,以及将其中的原料进行等同或等效的替换,而未能产生新的实质性特点和显著进步的,均应在本发明的保护范围之内。The present invention is further illustrated below through several embodiments. It should be understood that all the examples listed are to help those skilled in the art to understand and implement the present invention, and not to limit the present invention in any form. All simple improvements and adjustments made on the basis of the present invention, as well as the equivalent or equivalent replacement of the raw materials, which fail to produce new substantive features and significant progress, shall be within the protection scope of the present invention .
实施例1 组合物处方示例Example 1 Composition prescription example
以下给出数个示例处方,并指出了各处方适用范围和对象。需要注意,所列处方并非是任何对处方组成的限定,仅为具体举例说明之用。本领域技术人员可以根据疾病表现的证状不同,病人的体质差异对处方进行调整,这些调整应同样纳入本发明的保护范围之内。Several example prescriptions are given below, and the scope and object of each prescription are indicated. It should be noted that the listed prescriptions are not any restrictions on the composition of the prescriptions, but are only for specific examples. Those skilled in the art can adjust the prescription according to the different symptoms of the disease and the difference in the patient's constitution, and these adjustments should also be included in the protection scope of the present invention.
处方1Prescription 1
黄精45g 藏菖蒲25g 诃子17g 石菖蒲35gPolygonatum 45g Tibetan calamus 25g Myrobalan 17g Shichangpu 35g
毛诃子45g 东方草莓23g 藏红花5g 儿茶膏5gMyrobalan 45g, oriental strawberry 23g, saffron 5g, catechin cream 5g
处方2Prescription 2
黄精45g 藏菖蒲25g 诃子17g 石菖蒲35gPolygonatum 45g Tibetan calamus 25g Myrobalan 17g Shichangpu 35g
毛诃子45g 东方草莓23g 藏红花5g 儿茶膏5gMyrobalan 45g, oriental strawberry 23g, saffron 5g, catechin cream 5g
珠芽景天29gSedum japonicum 29g
处方3Prescription 3
黄精45g 藏菖蒲25g 诃子17g 石菖蒲35gPolygonatum 45g Tibetan calamus 25g Myrobalan 17g Shichangpu 35g
毛诃子45g 东方草莓23g 藏红花5g 儿茶膏5gMyrobalan 45g, oriental strawberry 23g, saffron 5g, catechin cream 5g
珠芽景天29g 鼠曲草34gSedum japonicum 29g and sagegrass 34g
处方4Prescription 4
黄精37g 藏菖蒲20g 诃子10g 石菖蒲35gPolygonatum 37g Tibetan calamus 20g Myrobalan 10g Shichangpu 35g
毛诃子45g 东方草莓23g 藏红花5g 儿茶膏5gMyrobalan 45g, oriental strawberry 23g, saffron 5g, catechin cream 5g
珠芽景天29g 乳白香青30gSedum sedum 29g Milky white fragrant green 30g
处方5Prescription 5
黄精25g 藏菖蒲22g 诃子12g 石菖蒲32gPolygonatum 25g Tibetan calamus 22g Myrobalan 12g Shichangpu 32g
毛诃子41g 东方草莓20g 藏红花3g 儿茶膏6gMyrobalan 41g, oriental strawberry 20g, saffron 3g, catechin cream 6g
珠芽景天24g 鼠曲草28g 黄芪5g 五爪龙3gBud sedum 24g, sage grass 28g, astragalus 5g, five-clawed dragon 3g
处方6Prescription 6
黄精25g 藏菖蒲22g 诃子12g 石菖蒲32gPolygonatum 25g Tibetan calamus 22g Myrobalan 12g Shichangpu 32g
毛诃子41g 东方草莓20g 藏红花3g 儿茶膏6gMyrobalan 41g, oriental strawberry 20g, saffron 3g, catechin cream 6g
珠芽景天24g 鼠曲草28g 法半夏5g 五味子5gSedum sedum 24g, sage grass 28g, pinellia 5g, schisandra 5g
陈皮7gChenpi 7g
处方7Prescription 7
黄精25g 藏菖蒲22g 诃子12g 石菖蒲32gPolygonatum 25g Tibetan calamus 22g Myrobalan 12g Shichangpu 32g
毛诃子41g 东方草莓20g 藏红花3g 儿茶膏6gMyrobalan 41g, oriental strawberry 20g, saffron 3g, catechin cream 6g
珠芽景天24g 乳白香青28g 冬虫夏草10gBud sedum 24g Milky white fragrant green 28g Cordyceps sinensis 10g
处方8Prescription 8
黄精25g 藏菖蒲15g 诃子12g 石菖蒲16gPolygonatum 25g Tibetan calamus 15g Myrobalan 12g Shichangpu 16g
毛诃子27g 东方草莓10g 藏红花4g 儿茶膏4gMyrobalan 27g, oriental strawberry 10g, saffron 4g, catechu cream 4g
珠芽景天8g 鼠曲草18g 菟丝子4g 制何首乌2gSedum sedum 8g, sagema 18g, dodder 4g, Polygonum multiflorum 2g
实施例2 制剂示例Example 2 Preparation Example
示例1 散剂制剂Example 1 Powder formulation
①提供实施例1中处方4所述的组合物。① provide the composition described in prescription 4 in embodiment 1.
②各组分研细后混匀即得。② Grind each component finely and mix well.
示例2 散剂制剂Example 2 Powder formulation
①提供实施例1中处方6所述的组合物。① provide the composition described in prescription 6 in embodiment 1.
②各组分研细后混匀即得。② Grind each component finely and mix well.
示例3 口服液制剂Example 3 Oral liquid preparation
①提供实施例1中处方2所述的组合物。① provide the composition described in prescription 2 in embodiment 1.
②各组分研细后,以水浸泡至少2小时后,再煎煮2次,每次2小时。每次煎煮结束均过滤收集煎煮液。②Grind each component finely, soak in water for at least 2 hours, then decoct twice, 2 hours each time. The decoction was collected by filtration at the end of each decoction.
③合并煎煮液,减压浓缩,过滤取清液。③Combine the decoction liquid, concentrate under reduced pressure, and filter to get the clear liquid.
④取白蜜10g,加水适量溶解成蜜糖水,将③中清液用蜜糖水稀释,搅拌,即得。④Take 10g of white honey, add appropriate amount of water to dissolve it into honey water, dilute the clear liquid in ③ with honey water, stir, and you get it.
示例4 硬胶囊制剂Example 4 Hard Capsule Formulation
①提供实施例1中处方6所述的组合物。① provide the composition described in prescription 6 in embodiment 1.
②各组分研细后,以95%乙醇浸泡至少14h,如此浸泡3-4次至浸泡液色淡,合并浸泡液,过滤。②After finely grinding each component, soak in 95% ethanol for at least 14 hours, soak in this way for 3-4 times until the color of the soaking liquid is light, combine the soaking liquid, and filter.
③滤后液减压浓缩制成干浸膏,加适量助流剂或润滑剂,如硬脂酸镁、滑石粉等,混匀,送入包衣锅中,将润湿剂如乙醇或水以雾状喷入,使粉末湿润粘合成粒,继续滚转至颗粒干燥。③ After the filtered liquid is concentrated under reduced pressure to make a dry extract, add an appropriate amount of glidant or lubricant, such as magnesium stearate, talcum powder, etc., mix well, send it into a coating pan, and add a wetting agent such as ethanol or water Spray in the form of mist to make the powder wet and bonded into granules, and continue to roll until the granules are dry.
④取药用空心胶囊,置于胶囊装填板上,将③中颗粒填充进入胶囊,锁合胶囊。④Take the medicinal empty capsule, place it on the capsule filling plate, fill the granules in ③ into the capsule, and lock the capsule.
需注意,以上制剂示例均是建立在少量制作的基础上。当需要大批量生产时,处方中各主要用量应等比例扩大,同时采用合适的工业化生产设备,如使用包括液体灌装机、粉末压片机、胶囊装填机、包衣机等。It should be noted that the above preparation examples are all based on a small amount of production. When large-scale production is required, the main dosage in the prescription should be increased in proportion, and appropriate industrial production equipment should be used at the same time, such as liquid filling machines, powder tablet presses, capsule filling machines, coating machines, etc.
实施例3 动物药效实验Embodiment 3 animal efficacy experiment
1、免疫性重症肌无力小鼠动物模型建立1. Establishment of mouse animal model of immune myasthenia gravis
以加利福尼亚电鳗电器官AChR(T. Californica AChR)与完全弗氏佐剂(CFA)1:2比例制备抗原乳剂。取C57BL/6小鼠(体重16g左右),将抗原乳液于小鼠双后足垫、尾根部、背部多点注射,注射量为100μL。1d后追加注射一次,共追加2次。观察小鼠活动情况,于第9d出现尾部活动无力症状,第10d出现双后肢无力症状,认为造模成功。The antigen emulsion was prepared at a ratio of 1:2 between T. California AChR and complete Freund's adjuvant (CFA). Take a C57BL/6 mouse (about 16 g in weight), and inject the antigen emulsion at multiple points on the mouse's hind foot pads, tail base, and back, with an injection volume of 100 μL. One additional injection was given after 1 day, for a total of 2 additional injections. The activity of the mice was observed, and the weakness of the tail appeared on the 9th day, and the weakness of both hind limbs appeared on the 10th day, and the modeling was considered successful.
将处方1、4、6、7所示药物分别用0.5%羧甲基纤维素钠混悬,使药物的质量体积浓度为71mg/mL;Suspend the drugs shown in prescriptions 1, 4, 6, and 7 with 0.5% sodium carboxymethylcellulose, so that the mass volume concentration of the drug is 71 mg/mL;
2、分组与实验2. Grouping and experiment
将模型小鼠随机分为6组,分佐剂对照组、阳性对照组,中药组1-4组,每组10只。另取健康小鼠10只为正常对照组。阳性对照药物为地塞米松,灌胃(0.2mg/kg体重),每日一次,中药1-4组为处方1、4、6、7所示药物的悬浮液,灌胃量为1ml/kg体重,每日一次;阴性对照组为与药物组等体积的0.5%羧甲基纤维素钠溶液灌胃,每日一次,佐剂组为与药物组等体积的完全弗氏佐剂灌胃,每日一次。于28d后,各组小鼠停止给药,继续观察28d。The model mice were randomly divided into 6 groups, including adjuvant control group, positive control group, and Chinese medicine group 1-4, with 10 mice in each group. Another 10 healthy mice were used as the normal control group. Positive control drug is dexamethasone, intragastric administration (0.2mg/kg body weight), once a day, traditional Chinese medicine 1-4 group is the suspension of the drug indicated in prescription 1, 4, 6, 7, intragastric administration volume is 1ml/kg body weight, once a day; the negative control group was administered intragastrically with 0.5% sodium carboxymethylcellulose solution equal to the volume of the drug group, once a day; once a day. After 28 days, the mice in each group stopped the administration and continued to observe for 28 days.
3、结果3. Results
(1)连续给药的前28d中,小鼠体重变化情况(1) Changes in body weight of mice during the first 28 days of continuous administration
称量各组小鼠0d、7d、14d、21d、28d体重,记录平均体重(单位:g)。The mice in each group were weighed on 0d, 7d, 14d, 21d, and 28d, and the average body weight was recorded (unit: g).
*注:佐剂组于第15d有一只小鼠死亡,第26d有二只小鼠死亡。*Note: In the adjuvant group, one mouse died on the 15th day, and two mice died on the 26th day.
(2)第28d完成最后一次给药后,停止给药,小鼠的体重变化情况(2) After the last administration on the 28th day, the administration was stopped, and the changes in the body weight of the mice
称量各组小鼠35d、42d、49d、56d体重,记录平均体重(单位:g)。The mice in each group were weighed on 35d, 42d, 49d, and 56d, and the average body weight was recorded (unit: g).
*注:阳性组与第37d有一只小鼠死亡,第46d有三只小鼠死亡,第52d有二只小鼠死亡。共计6只小鼠死亡,死亡率60%。*Note: In the positive group, one mouse died on the 37th day, three mice died on the 46th day, and two mice died on the 52d day. A total of 6 mice died, the mortality rate was 60%.
**注:佐剂组于第33d有一只小鼠死亡,第34d有三只小鼠死亡,第42d有二只小鼠死亡,第45d最后1只小鼠死亡(体重为8.0g)。共计10只小鼠死亡,死亡率100%。**Note: In the adjuvant group, one mouse died on the 33rd day, three mice died on the 34th day, two mice died on the 42d day, and the last mouse died on the 45th day (body weight 8.0g). A total of 10 mice died, the mortality rate was 100%.
结论:in conclusion:
①未给药治疗的实验组小鼠随时间推移病情加重,逐渐导致咀嚼无力而难以进食,导致体重下降;病情较重者出现死亡例。①The condition of mice in the experimental group without drug treatment worsened over time, gradually leading to weakness in chewing and difficulty in eating, resulting in weight loss; those with severe conditions died.
②阳性组给与地塞米松治疗,缓解了小鼠因肌无力导致的难以进食的病状,从而能部分恢复正常活动饮食,随着治疗的持续进行,体重有所增加,当停止给药治疗后,再次出现体重下降,并出现死亡个体,说明持续1个月的地塞米松给药治疗未能根本治疗小鼠重症肌无力。② The positive group was treated with dexamethasone, which alleviated the difficulty of eating due to muscle weakness in the mice, so that they could partially resume normal activities and diet. As the treatment continued, the body weight increased. , body weight decreased again, and a dead individual appeared, indicating that the administration of dexamethasone for 1 month failed to fundamentally treat myasthenia gravis in mice.
③中药组以本发明提供的中药组合物给药,起效较慢,但药效较为持久,整体效果与阳性组基本一致,于28d基本恢复到正常小鼠的体重水平,在停止给药后,未出现死亡个体,体重也未有明显下降,基本保持稳定。③The Chinese medicine group was administered with the Chinese medicine composition provided by the present invention, and the onset of effect was slow, but the drug effect was relatively long-lasting, and the overall effect was basically the same as that of the positive group, and basically returned to the body weight level of normal mice at 28 days. , there were no dead individuals, and the body weight did not drop significantly, and remained basically stable.
该实验结果表明,本发明提供的中药组合物能够改善小鼠重症肌无力模型的症状,同时与地塞米松治疗相比,具有药效持久的优势。药效持久的原因可能在于,本发明提供的中药组合物重建了小鼠受损的免疫系统。The experimental results show that the traditional Chinese medicine composition provided by the invention can improve the symptoms of the mouse model of myasthenia gravis, and at the same time, compared with dexamethasone treatment, it has the advantage of lasting drug effect. The reason for the long-lasting drug effect may be that the traditional Chinese medicine composition provided by the present invention rebuilds the damaged immune system of mice.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510777945.9A CN105232958B (en) | 2015-11-16 | 2015-11-16 | Traditional Chinese medicine composition for preparing medicine for treating myasthenia gravis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510777945.9A CN105232958B (en) | 2015-11-16 | 2015-11-16 | Traditional Chinese medicine composition for preparing medicine for treating myasthenia gravis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105232958A CN105232958A (en) | 2016-01-13 |
| CN105232958B true CN105232958B (en) | 2017-12-22 |
Family
ID=55030952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510777945.9A Active CN105232958B (en) | 2015-11-16 | 2015-11-16 | Traditional Chinese medicine composition for preparing medicine for treating myasthenia gravis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105232958B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250675B (en) * | 2015-11-17 | 2017-12-22 | 浏阳市利美免疫力修复中心有限公司 | Traditional Chinese medicine composition for preparing medicine for treating tumors |
| CN105232962B (en) * | 2015-11-17 | 2018-04-06 | 浏阳市利美免疫力修复中心有限公司 | A kind of traditional Chinese medicine composition for preparing medicine for treating skin diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1161849A (en) * | 1997-01-31 | 1997-10-15 | 白玛加措 | Tibetan preparatory medicine and preparation method thereof |
| CN1857329A (en) * | 2006-03-02 | 2006-11-08 | 甘肃奇正藏药有限公司 | Preparing method of Chinese medicine composition with starch |
-
2015
- 2015-11-16 CN CN201510777945.9A patent/CN105232958B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1161849A (en) * | 1997-01-31 | 1997-10-15 | 白玛加措 | Tibetan preparatory medicine and preparation method thereof |
| CN1857329A (en) * | 2006-03-02 | 2006-11-08 | 甘肃奇正藏药有限公司 | Preparing method of Chinese medicine composition with starch |
Non-Patent Citations (2)
| Title |
|---|
| 藏医藏药治疗风湿病88例临床观察;龙巴;《医学文选》;20010331;第20卷(第1期);第64-65页 * |
| 藏药桑当聂莪治疗类风湿性关节炎210例;尕日毛;《中国民族医药杂志》;20040131(第1期);第9页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105232958A (en) | 2016-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103169903B (en) | Traditional Chinese medicine preparation for treating child bronchitis and preparation method thereof | |
| CN111317798A (en) | Traditional Chinese medicine composition for detoxifying, eliminating dampness and relieving sore throat and application thereof | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN105250675B (en) | Traditional Chinese medicine composition for preparing medicine for treating tumors | |
| CN105232958B (en) | Traditional Chinese medicine composition for preparing medicine for treating myasthenia gravis | |
| CN104173517A (en) | Traditional Chinese medicine preparation and preparation method for treating primary trigeminal neuralgia | |
| CN101983695A (en) | Traditional Chinese medicine composition for curing hemiplegia and preparation method thereof | |
| CN105963467A (en) | Traditional Chinese medicine composition, application thereof and preparation | |
| CN105232959B (en) | A Chinese medicinal composition | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN105232962B (en) | A kind of traditional Chinese medicine composition for preparing medicine for treating skin diseases | |
| CN111407808A (en) | Epidemic-resistant traditional Chinese medicine composition, preparation method and pharmaceutical application thereof | |
| CN118252889B (en) | Medicine for treating herpes zoster and preparation method thereof | |
| CN103520475B (en) | A kind of pharmaceutical composition being used for the treatment of skin pruritus | |
| CN120550026A (en) | A Chinese medicine composition and its application | |
| CN108295221B (en) | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof | |
| CN105878996A (en) | Traditional Chinese medicine composition for treating emphysema | |
| CN118490778A (en) | A Chinese medicine composition for treating African swine fever and its application | |
| CN104758442A (en) | Traditional Chinese medicine compound preparation for preventing and treating bronchial asthma and preparation method of traditional Chinese medicine compound preparation | |
| CN121490025A (en) | A traditional Chinese medicine composition for treating atrophic gastritis and its preparation method | |
| CN103356984B (en) | Traditional Chinese medicine composition for preventing and treating female iron deficiency anemia | |
| CN121177386A (en) | A traditional Chinese medicine composition for treating sinusitis, its preparation method and application | |
| CN113318167A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis | |
| CN104491278A (en) | Traditional Chinese medicinal composition for treating leucoderma due to qi stagnation and blood stasis | |
| CN111388578A (en) | Traditional Chinese medicine composition for treating facial paralysis as well as preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200901 Address after: 410331 Kaiyuan Avenue Erkang Pharmaceutical Co., Ltd Patentee after: Liuyang Limei hospital Co., Ltd Address before: 410331 No. 167, Kangping Road, Liuyang economic and Technological Development Zone, Changsha, Hunan Patentee before: LIUYANG LIMEI IMMUNITY REHABILITATION CENTER Co.,Ltd. |